YEARBOOK 2018
THE ME DICON VA LLE Y
YEARBOOK
2 018
BIOTECH
CMO’S
REGULATORY COMPLIANCE
FASTEST GROWING
DISRUPTION HITS
INCREASED NUMBER
INDUSTRY
THE CMO MARKET
OF REQUIREMENTS
LIFE SCIENCE TALENTS
MEDTECH
PHARMACEUTICAL
CAMPAIGN WILL SEEK
HIGH EXPECTATIONS OF
ACKNOWLEDGEMENT
TO ATTRACT THE VERY
THE GOVERNMENT’S LIFE
OF THE INDUSTRY IS A
BEST
SCIENCE GROWTH PLAN
BREAKTHROUGH
March 2018 Publisher:
Høffdingsvej 34 2500 Valby Denmark E-mail: nem@nemmedia.dk Web: www.nemmedia.dk Editors: Karin Jensen Charlotte Strøm Arne Nielsen Clara Holm-Hansen and Mohammed Ali Wachah. Graphics & Layout: Kapteina Reklame Advertisement: Mohammed Ali Wachah +45 23238082 mw@nemmedia.dk Rasmus Andersen +45 42811110 ra@nemmedia.dk
CONTENTS THE COLUMN By Søren Bregenholt, Medicon Valley Alliance
4
WHAT HAPPENED IN 2017 A Look Back
6
INTERNATIONAL LIFE SCIENCE TALENTS Campaign Will Seek to Attract the Very Best
18
REGULATORY COMPLIANCE Finding the Balance
22
ONE BY ONE - SECTION OVERVIEW
26
BIOTECH 30
MEDTECH 35
PHARMA 38
CRO's 42
CMO's 48
BUSINESS SERVICE PROVIDERS 50
LABORATORY & MEDICAL EQUIPMENT 56
COMPANY INDEX
62
CALENDAR Highlighted Fairs & Events
74
Print: Green Graphic & Signtec Reklame In cooperation with:
Cross-cultural management, cooperation and communication We help staff at major life science organisations succeed in an international multicultural working environment. Our activities include: Management and cooperation in the multicultural team
•
Knowledge-sharing
•
•
Negotiation techniques
Feedback techniques
•
•
Presentation techniques
Scientific and business English
•
Translation and proofreading
•
ISSN: 2446-1776
2
www.global-denmark.dk +45 33 86 29 30
global@global-denmark.dk
Bringing life science professionals together
JOIN MEDICON VALLEY ALLIANCE
- your chance to tap into a handful of life science professional networks in the DanishSwedish Greater Copenhagen region
CREATE OPPORTUNITY NETWORK & EXPAND INNOVATION & RESEARCH Visit www.mva.org to learn more about the benefits and costs of MVA membership, how to join the networks and who you can expect to meet at which types of MVA events. Feel free to contact MVA Head of Communication & Public Affairs, David Munis Zepernick (dz@mva.org), or Senior Project Manager, Helen Pettersson (hp@mva.org), for a non-committal meeting.
Executive
Club Club
medicon valley
THE COLUMN
Let´s pick up the gauntlet! By Søren Bregenholt, Medicon Valley Alliance chairman of the Board and Corporate Vice President, Novo Nordisk ” La france a perdu une bataille mais la france n'a pas perdu la
University and the local Swedish life science community as such
guerre!” (France has lost a battle, but France hasn´t lost the war)
have very proactively reached out to Denmark and contributed to the realization of our joint regional vision. Hopefully, the
The famous and somewhat dramatic 1940 quote from French
national policy makers in Stockholm, although some 600 km
general, later president, Charles de Gaulle, has been used ever
away from the Medicon Valley life science hotspot, will also find
since to encourage someone to fight on despite even very serious
it useful to prioritize life science in Sweden’s southern region
setbacks.
as part of their upcoming national strategy. By mobilizing national, regional, public and private, academia and indus-
The situation in Greater Copenhagen, following the strong but
try, we can build and develop a first-class life science
unfortunately failed effort to attract the European Medicines
cluster to the benefit of Danish and Swedish R&D,
Agency, is fortunately less dramatic. But in terms of motivation,
Danish and Swedish industry, Danish and Swedish
dedication and unity, we now face a similar challenge.
employment and welfare and last but certainly not
We need to work together, plan ahead and mobilize support for
least Danish and Swedish healthcare. Only life sci-
our vision of a world-class Danish-Swedish life science cluster.
ence can deliver the same unique combination of
We must effectively put the Medicon Valley region on the global
societal benefits and in no other industry sector
life science map and firmly position the region as the leading
are Denmark and Sweden together so uniquely
life science cluster in Northern Europe.
positioned to harvest the fruits of strengthened
In the spring of last year, The Danish life science growth
ply the best business case we have got
collaboration. Investments in life science is simteam delivered 17 recommendations to a national life science strategy. They definitely point in the right direction; more
The potential is bigger than ever, and 2018
investment in public sector R&D, the need for talent attraction,
will show if we have what it takes to grasp this
coordination of clinical research, a home market that functions
opportunity. Reproductive health, oncology,
more convincingly as an international show-case, and better
dermatology, CNS and diabetes are already
tax incentives for research-intensive companies are among the
established scientific strongholds in Medicon
specific recommendations.
Valley. With Europe's largest life science conference, BIO Europe, coming to Copenhagen
Sweden´s has chosen a different process, but the objective to
in November, we have an excellent opportu-
have a national strategy for the future of Swedish life science is
nity to showcase our groundbreaking R&D,
the same. It is my hope, that these parallel processes will soon
our innovative companies and our attractive
merge into coordinated efforts between our two countries. Since
living and working conditions to the world of
Copenhagen and most of the Danish life science stakeholders
life science.
are located in the Medicon Valley region, the inclusion of the regional perspective would seem obvious. Region Skåne, Lund
4
But we have to agree to pick up the gauntlet!
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
SHARING EXPERTISE
Like no other. This is why we make all the difference The only truly optimised solution for Intensive care units and Anesthesia is CIS by Daintel because no other solutions on the market has been developed with the input of so many Clinicians in such an agile manner.
Be tough on the specs! Too many ICUs have poor clinical IT tools for one simple reason: poor specs. Always be precise, specific, and insist on tough clinical specs.
Newest facts for your next tender
• • • • • • • • • • •
e have implemented CIS with a full integration W to the Hospital Information System ●We have the only ICU solution with dynamic and integrated drug dosage suggestions ●We have been working with Qualcomm connectivity technology for over 10 years ●We have no hidden costs; all drivers are included ●We have over 1.200 observations in the chart ●We have the most flexible clinical user interface ●We install “plug & play” connectivity to medical devices ●We have fully automated fluid balance calculation ●We always store data in high resolution ●We can extract millions of records for research in minutes ●A nd so much more...
We are the only ICU solution to have ever received the prize for the best European Healthcare IT solution.
5
WHAT WE LEARNED
WHAT HAPPENED CLINICAL TRIAL ACTIVITY IMPROVES HEALTH CARE, EMPLOYMENT, AND LEARNING Edited by Arne Nielsen In 2017 The Danish Association of the Pharmaceutical
as well as an interest in strengthening the scientific
Industry (LIF), the NEXT Partnership, and Invest in Denmark
network. Moreover, clinical trials tend to implicate clinical
released a report provided by Copenhagen Economics
improvements at participating hospitals e.g. by changes made
quantifying the value of industry initiated clinical trials in
to daily clinical practice, treatment guidelines, changes made
Denmark.
to national guidelines etc.1 Furthermore, the respondents
The report puts into numbers the effects that may appear difficult to quantify properly, such as the learnings and knowledge sharing among health care professionals from working with a clinical trial. More than 53% of respondents agreed that they felt working with clinical trials had
pointed to a trend that clinical trial activity subsequently resulted in increased scientific activity taking place at the institution, i.e. attracting more clinical trials or other research activities, publication of scientific results directly or indirectly related to the clinical trial etc.
improved their clinical skills, and 61% responded that their
Clinical trials initiated by the life science industry tend to
knowledge had been shared with colleagues.1
attract millions in investments, improving capacity and
The motivation among health care professionals to join clinical trials as investigators covers a professional interest in being part of the most recent pharmaceutical development
1
qualifications with the staff. Moreover, the industry initiated clinical trials also create jobs and improve the gross national product.
Source Værdien af kliniske forsøg i Danmark. NEXT Partnership, Lægemiddelindustriforeningen og Invest in Denmark. Jan 2017.
http://lif.dk/SiteCollectionDocuments/Analyser%20mv/V%C3%A6rdien%20af%20kliniske%20fors%C3%B8g%20i%20Danmark%2030JAN17.pdf
RAISED APPLICATION FEES AND OVERHEAD COSTS PUT STRAIN ON CLINICAL TRIAL BUDGETS Edited by Arne Nielsen Through an executive order the Danish Medicines Agency
Critics of the raise of fees at DKMA claim that the increase
(DKMA) raised the fees to be paid to the agency for
in costs may jeopardize the activity on clinical trials. The
applications on clinical trials of medicinal products as of
Danish Medical Association worries on the raised fees
the 1st of July 2017. The fees apply to all, irrespective of the
particularly concerning the investigator initiated trials. The
origin of the trial sponsor.
Danish Association of the Pharmaceutical Industry (LIF) also
During the public hearing prior to the decision made by the
raised concern regarding the increase in fees.
Minister of Health, Ellen Trane Nørby, several stakeholders
LIF has compared the level of fees with the National
raised their concerns on the remarkable raise in the fees.
Competent Authorities in 17 European countries. The key
An application involving new medicinal products from 01
concern with the numbers is that the fees in Denmark are
July 2017 costs 6.087 EUR, applications involving already
now in the high end.
marketed products cost 3.066 EUR. Additionally, as a new item, an annual fee of 1.711 EUR applies to every trial for every ongoing year. Amendments to the protocol cost 635
The Minister of Health, Ellen Trane Nørby, suggested that the raised fees will be subject to evaluation after some time.
EUR. Overall, the fees have been raised considerably.
6
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
SHARING EXPERTISE
Just in case... You didn’t read the previous page. CIS by Daintel is the only truly optimised solution for Intensive Care units and Anaesthesia. See the facts on the previous page or get a FREE fully functioning version of CIS installed free of charge in your department. Too good to be true? Pick up the phone and hear the offer for real.
Get a free CIS, installed in your ICU. We are so confident about our solution that we offer you a free fully functional installed CIS version in your ICU or Operation Room*.
The competition would never dare giving you the same offer. Contact our CEO on ph@daintel.com
www.daintel.com - a supplier you can trust.
Daintel ApS Diplomvej 381, 2800 Kongens Lyngby | +45 7027 4470 *Terms and conditions apply.
WHAT WE LEARNED
MEDICON VALLEY ALLIANCE CELEBRATED ITS 20 YEARS ANNIVERSARY Edited by Arne Nielsen Members, life science collaborators, and academia joined the
only across the bridge but also across sectors, in the political
20 years anniversary reception of Medicon Valley Allicance
community, academia, and the industry as drivers of growth.
(MVA) in august 2017.
Sindra Peterssson Årsköld, Senior Adviser, enthusiastically
Since the beginning in 1997 the life science organization,
told the audience about the vision and ambitions for the
MVA, has watched the cluster thrive and grow into the
European Spallation Source (ESS), a true example of what
largest life science cluster in the Nordic. CEO at MVA, Petter
Region Skåne and Capital Region Denmark is capable of when
Hartman, welcomed the guests and on a running basis
joining forces, resources, man power, and talent. The ESS will
introduced the speakers who were invited to put into few
open in 2023 and will improve the scientific possibilities and
words what the scientific perspectives are for this Danish-
potential within a range of different disciplines.
Swedish connection.
Thomas Kongstad Petersen, Chairman of NEXT Partnership
Søren Bregenholt, Chairman of the MVA Board and Corporate
and Vice President at LEO Pharma highlighted that the NEXT
Vice President at Novo Nordisk highlighted that the MVA
partnership has proven to be a successful way to attract the
as organization has three equally important pillars: Strong
early phase clinical trials to the region. Albeit there is still
academic institutions, cutting edge health care sector and a
a lot of work to be done in order to improve the framework
vibrant life science environment.
conditions, he pointed out that he is convinced that the puplic-private partnerships are here to stay.
Joining forces Lars Gaardhøj (Socialdemokratiet), Chairman of the Business and Growth Committee in the Capital Region of Denmark puts effort on the high ambitions for collaborations, not
With the courtesy of Copenhagen University, the Vice Dean, Trine Winterø, co-hosted the anniversary reception at the top of the Maersk Tower at the Panum Institute in the midst of Copenhagen.
THE GOVERNMENT’S GROWTH TEAM FOR LIFE SCIENCE DELIVERED 17 RECOMMENDATIONS Edited by Arne Nielsen Earlier last year, the government’s growth team for Life
make sure that the educational system can deliver the right
Science delivered 17 recommendations on how to improve the
competencies in future. Politicians, universities and industry
framework conditions so that the industry can create growth,
must work closely together.
develop new innovative treatments, strengthen research and innovation and increase exports.
investments on the Swedish side of Oresund. I think Denmark
We asked Medicon Valley Alliance, the Danish-Swedish life
can benefit from investments in Sweden, for example the
science networking organisation about their view on the
ESS (European Spallation Source), MAX IX Laboratory at the
recommendations.
Lund University, where ground-breaking research is being
Petter Hartman, CEO Medicon Valley Alliance (MVA): ”Overall, it’s a really ambitious job that’s been done here with some strong recommendations. If these are implemented the right way, then it can have real significance but it’s now up to politicians to create the right conditions.
done. “The third important part of the recommendations is the entire banding aspect, to visualise the position of strength we have and become even better at marketing the region and make it attractive for international talents and investors to look towards Denmark. For Greater Copenhagen to be
”For MVA, what we’re especially interested in is access to
perceived as a leading Life Science hub, marketing and
qualified labour. This is the key issue. We have to work really
internationalisation are enormously important.
hard in the region to attract international talents but also to
8
“Investments in research is another important area, also
(More related to this topic on pages 30-40)
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | M A RC H 2018
WHAT WE LEARNED
THE 17 RECOMMENDATIONS ARE: 1.
2.
Denmark should allocate more resources to and target the public research as well as increase the private research, which form the basis of innovation within Danish Life Science. At the same time, the education of highly qualified researchers to the private and the public sector should be reinforced. The coordination of clinical research in Denmark should be gathered in one unifying place under the existing NEXT cooperation which should be expanded into a national organization covering all clinical areas. The new NEXT 2.0 is anchored between state, regions and companies, and the possibilities of clinical research at the hospitals are enhanced.
3.
Efforts to create the framework for transparency and trusting public-private cooperation between healthcare sector and companies should be enhanced.
4.
It should be possible to use IT and health data in a secure manner in order to develop and research in new and innovative forms of treatment and to contribute to a better, more secure and coherent healthcare sector.
5.
The Danish Medicines Agency should be reinforced to be one of the top medicines agencies in Europe.
6.
There should be more notified bodies (bodies that certify medical devices) in Denmark with the relevant top quality capacity to meet demands.
7.
Denmark should be a pioneering country within personal health technology.
8.
The Danish education system should be organized so it can, to a higher degree, deliver world-class employees with the right skills for the entire value chain within the Danish Life Science industry.
9.
Danish Life Science is global - and the conditions for attracting and keeping international talents and qualified labour should be at the European top.
10. Denmark should increase the focus on entrepreneurship and innovation within the Life Science research and education environments as well as improve the conditions for this.
11. Denmark should pave the way for more Life Science
companies through better access to early financing.
12. Opportunities for attracting investments for Danish Life Science companies should be enhanced.
13. The tax incentives for research-intensive companies and for investors should be improved.
14. In Denmark Life Science companies should have a fa-
vorable framework for manufacturing with research and development as a basis.
15. Continuous work has to be done to support a flexible,
stable, rational and innovation-boosting home market that can work as an international show window.
16. A national exporting strategy for Life Science should be prepared and this should be supported by new earmarked funds for export-promoting activities with the aim that the export of Danish Life Science solutions should be doubled towards 2025. Moreover, an action plan should be prepared to form the basis of increased targeted efforts to attract foreign investments to the Danish Life Science group.
17. A growth plan for Life Science should be prepared based on the Growth Team's recommendations and a permanent Life Science office referring to the Danish Minister for Industry, Business and Financial Affairs should be established.
EMA FOUND A NEW HOME Edited by Arne Nielsen One of the consequences of the United Kingdom’s vote to
a new location. The big question in 2017 was where. The
leave the European Union comes into act by 1 April 2019
answer was found in November 2017, and EMA will relocate
when the European Medicines Agency (EMA) will open in
to Amsterdam.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | M A RC H 2018
9
WHAT WE LEARNED
LIFE SCIENCE HIGHLIGHTS FROM FOLKEMØDET 2017 More than 100.000 visitors over four days at the annual political festival, Folkemødet, 15-18 June at Bornholm participated in around 3.200 different events. Among them were a lot of events related to life science. Edited by Arne Nielsen Politicians and people, representing private companies, public organizations, NGO’s, and the media gathered to discuss and debate all kinds of topics during the major annual stakeholder event, Folkemødet. Events related to life science enclosed topics such as patient safety, medical innovation and growth, clinical trials, healthcare technology, personalized medicine, big data, education, impartiality in healthcare decisions, transparency, and much more. By end March 2017 the Growth Team on Life Science under the Ministry of Industry, Business, and Financial Affairs presented 17 recommendations to support and further develop life science growth. Anders Thelborg from the Growth Team on Life Science pointed to the need for an office to govern, coordinate, and provide assistance for life science in the same manner as what is seen in agricultural and maritime business areas as top of the wish list. Christian Vintergaard from The Danish Foundation for Entrepreneurship stressed that the universities focus too little on entrepreneurship. Dean Ulla Wewer from Copenhagen University underlined that providing competent candidates and a highly educated work force remains the key delivery of the universities.
Representatives from the Danish Medicines Agency, Kræftens Bekæmpelse as a major NGO, Siemens Healthcare, and Neurescue discussed how patient involvement drives innovation in life science. Siemens Healthcare outlined how customized patient applications and changes in existing equipment are readily based on patient feedback. Nikolaj Brun from the Danish Medicines Agency pointed out that any interaction that the Agency has with the pharmaceutical industry is highly transparent to the public, which is a foundation of the work of the Agency. And from a patient perspective, the involvement in clinical trials drives improved health and prognosis as stated by Leif Vestergaard, CEO at Kræftens Bekæmpelse. Several events discussed the opportunities and inborn potential ethical concerns related to the use of big data. Real world evidence has become an important tool in patient safety surveillance and treatment benefits in large populations. For more information: www.folkemoedet.dk
FOUR NEUROSCIENTISTS RECEIVE THE BRAIN PRIZE FOR CRUCIAL RESEARCH ON ALZHEIMER'S The tireless efforts of these four leading scientists to understand Alzheimer's have provided the foundation for treatment of one of the most devastating diseases of our era. For this, they are receiving the world's most valuable prize for brain research, The Lundbeck Foundation Brain Prize, worth 1 million euros. By Dr Kim Krogsgaard, Director of The Brain Prize
10
Denmark sees 7,500 new cases of dementia every year, changing the lives of Danish families for ever. 80,000 patients already live with some form of dementia – and, little by little, their brain cells are destroyed. Around 50,000 of these patients have Alzheimer's disease.
the world's most valuable prize for brain research, The 2018 Brain Prize, worth 1 million euros (approximately 7.5 million Danish kroner). This year’s prizewinners were announced on Tuesday, 6 March at the spring meeting of the Danish Society for Neuroscience.
There is still no cure for dementia such as Alzheimer's; we can only provide medication for temporary alleviation of symptoms, but thanks to four leading European scientists and their many years of intense research in the laboratory, the way is now paved for better treatment and, in time, prevention.
Together, these four internationally respected neuroscientists have revolutionised our understanding of the harmful changes in the brain that lead to Alzheimer's disease. Their research achievements form the basis for development of the drugs that are currently tested as therapies for the disease.
The four scientists are Bart De Strooper from Belgium, Michel Goedert from Luxembourg, Christian Haass from Germany and John Hardy from the UK. They are recognised for their highly specialised studies of Alzheimer's disease and other dementia disorders and are now being awarded
The organisation behind the prize is the Lundbeck Foundation, one of Denmark's largest sponsors of biomedical research. (www.thebrainprize.org/www.lundbeckfonden.com)
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
DIPLOMA IN CLINICAL PROJECT MANAGEMENT For you who works with clinical development and wishes to develop your competencies and skills within project management.
ADVANCED COURSES: Diploma in Clinical Project Management Site Audit and Inspections
In collaboration with Implement Learning Institute
Clinical Trial Management and Risk Based Monitoring Certificate in Advanced GCP
DIPLOMA PROGRAMMES: Diploma in ICH-GCP Managed Trials for Monitors and Investigators / Study Nurses
BASIC COURSES: Certificate in Basic GCP Introduction to Clinical Drug Research
Certified by: Read more at www.atriumcph.com or contact Programme Director Gitte Hornemann Møller at ghm@atriumcph.com
Implement Consulting Group has been reviewed and approved as a provider of project management training by the Project Management Institute (PMI)
The Only Complete Contamination Monitoring Solutions Provider
D
A
T A
M A N A G E M E
N
T
Contamination Monitors
STERILITY ASSURANCE
Services
Environmental Monitoring Systems
Training and Education
D
A
T
A
M M A N A G E
For more informtion contact us at:
pmeasuring.com T: +45 7070 2855 E: pmsnordic@pmeasuring.com
E
N
T
WHAT WE LEARNED
CELL-BASED THERAPY FOR MORE T1D PATIENTS By Clara Holm-Hansen The widespread prevalence of diabetes is growing, but only a few T1D patients are receiving cell-based therapy through transplantations of insulin-producing beta cells from deceased organ donors. The complex procedure requires technical purification and selection of millions1 of pancreatic islets, located on the lower stomach, for the therapy to work effectively. However, according to a new groundbreaking
study2, cell-based therapy might be a tangible reality for more patients with type 1 diabetes in the future. The study shows success in generating human pluripotent stem cells (hPSC) with the same properties as organ donated beta cells. A constant source of insulin-producing cells simply means that patients will have easier access to cell-based therapy and further treatment in the future.
1
https://www.niddk.nih.gov/health-information/diabetes/overview/insulin-medicines-treatments/pancreatic-islet-transplantation
2
http://www.cell.com/cell-reports/fulltext/S2211-1247(17)30364-9
NEW DEVELOPMENT IN MS GENE THERAPY By Clara Holm-Hansen A new study shows a possible treatment of multiple sclerosis by stimulating the immune system to inhibit harmful T-cells through gene therapy. After hundreds of attempts of treating mice with a condition similar to multiple sclerosis, researchers have recently seen a regrowth and repair of the myelin coating around the damaged nerves causing MS in mice. By using a unique molecule, obtained by implementing a gene from a myelin-based protein into a virus, the researchers were able to stimulate and ‘manipulate’ the immune system of the mice. The mice reacted to the
molecule by developing benign T-cells, which helped them become more tolerant to infections while inhibiting the ‘bad’ and more aggressive T-cells that caused the breakdown of myelin. The study takes advantage of basic scientific knowledge on how the body reacts to infections, which makes the gene-developed vector similar to a vaccine. Though the study holds great knowledge on neuro inflammation and MS gene therapy, it is not yet ready to be applied to humans at this stage.
GROUNDBREAKING CELL THERAPY TO TREAT LEUKEMIA By Clara Holm-Hansen In late 2017, US Food and Drug administration (FDA) approved a new cell-based CAR-T leukemia treatment that helped a 5-year old girl with aggressive leukemia get completely cancer free. Dr. Tim Cripe, who is part of the FDA committee, called the cancer treatment “one of the most exciting he’s ever witnessed”1. By developing blood cells genetically, the treatment has shown to be effective in treating children and adults with certain types of large B-cell lymphomas. The blood cells are manipulated to attack leukemia in the bloodstream by collecting and genetically
12
modifying the patient’s T-cells. This creates a new gene that kills the lymphoma cell. In other words, the treatment takes use of a patient’s own immune system to destroy the cancer1. Although the side effects from treating leukemia with CAR-T treatment is characterized by ‘severe’ – just like chemo therapy – it has cured several patients with fast-growing, late-stage leukemia. CAR-T is on its way to countries all around the world and is currently being used on leukemia patients in the US.
1
https://www.sciencealert.com/a-cancer-treatment-that-one-expert-called-the-most-exciting-thing-i-ve-seen-in-my-lifetime-just-got-approved
2
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581216.html
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
Experience in Cell and Gene Therapy Assures Success It’s never too soon to start personalizing the supply chain
Rapid advances in disease therapies based on living genes and cells hold the potential to cure the body, rather than simply treat a disease -- but only if they arrive in perfect condition, on time, every time.
39 sites. Maximum 24 hour transit time.
To achieve that, the logistics industry has to evolve with the science. Cell and gene therapies are produced one-by-one under strictly controlled conditions, using live bio-materials. Time and temperature variation could destroy them, so they must arrive at the clinical site on time and in pristine condition. In theory, that’s a tough job. In the real world, it’s much harder. Weather, air traffic, road conditions, climate zones, customs regulations and processing times can’t be allowed to delay delivery, or affect the temperaturecontrolled packaging of the samples and therapeutic materials. To ensure success, World Courier starts working with study sponsors years in advance. Our dedicated project team plans a personalized supply chain, develops customized operating procedures, trains all personnel who come in contact with the shipments from lab to clinic, and works with airlines personnel and international customs agents to make sure everyone knows what is at stake and how to handle the shipments.
In real life: a case study World Courier planned and executed all logistics for a developer of immuno-oncology products during a Phase II clinical trial. Under evaluation was an autologous, dendritic cell-based therapy for cancer patients, to extend remission
worldcourier.com contactus@worldcourier.com
time and possibly overall survival. The therapy was granted an orphan drug designation by the FDA and EMA, and received fast track designation by the FDA after the Phase II trial. The therapy owner’s manufacturing sites were located in Europe and in Australia. Shipments of starting cell material had 24 hours to travel from the clinical sites in Europe and Asia to the central manufacturing sites. Over a period of 20 months, World Courier delivered 245 shipments containing more than 2,000 kilograms of materials to treat 63 patients. Therapeutic materials traveled by air freight and road, and were hand carried to their final destination. Our clinical sample delivery success rate was 100%. The best logistics partner for your clinical trial is one who has been down that road before. To learn how we do it and what to look for in a personalized supply chain provider, please download our free e-book at www.worldcourier.com
SCIENCE PARKS
SCIENCE PARKS IN
MEDICON VALLEY
1
1 NOVI NOVI is one of Denmark’s biggest science parks holding more than 100 companies with a thousand employees. They seek to set up businesses within science and scientific entrepreneurships. As a network of innovative and creative companies, they continue to stand strong internationally while helping to generate growth and catalyze scientific protects. NOVI is in close cooperation with Aalborg University and its students to whom they offer
2
scholarships and scientific research opportunities.
2 INCUBA Research Park Located in Aarhus, Denmark, INCUBA Science Park was created with a primary goal to strengthen small scientific companies and research institutions. This has been made possible through professional consultancy and by raising capital for projects that strive to make a difference. They have recently held a lecture presenting the development of a new, effective cholesterol medicine based on basic research from Aarhus University. The project has received 2.5 million from the Novo Nordisk Foundation for development work.
3 CAPNOVA / CAT Science Park As an investment- and development company, Capnova seeks to catalyze entrepreneurship, ideas and innovations as a host and mentor within science. They have recently invested in an amazing surgical instrument, developed by two Danish engineers, that improves the treatment of lung patients. The instrument, called “KatGuide”, guides the pulmonary tract to the right place in the lung cavity creating more accurate operations
5 COBIS Copenhagen Bio Science Park (COBIS) holds an incomparable value for a lot of biotech companies - both internationally and in Denmark. COBIS is home to a wide range of organizations and companies in a 12.000 square foot building - a few minutes from Copenhagen - in ‘Medicon Valley’. They recently published news on Danish biotech company Acesion Pharma, who just got an approval of their drug addressing acute and persistent AF (Atrial Fibrillation) as an effective treatment for heart patients.
and fewer misplaced drainage cases.
6 Scion DTU
4 Symbion Symbion Science Park hosts conferences that aim to establish cooperation between researchers and innovators. It houses around 250 businesses that offer two growth programs. It was founded in 1986 by six scientists and approved by the Danish Ministry of Sciences shortly after as an ‘innovation environment’. Representing innovations within science, mediocre and artificial intelligence, the co-working space at
University based science park Scion DTU, who collaborates with companies within medico, biotech, cleantech and IT, has recently presented exciting news on methods to effectively diagnose heart patients. Danish life science startup MedTrace has developed a system that produces and injects a “radioactive water tracer” in a patient. They have created a unique solution that provides the most accurate and efficient diagnosis, so that heart patients can get the treatment they need.
Symbion offer exciting developments in all fields.
14
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
SCIENCE PARKS
- It takes more than four walls and a computer to create scientific results leading to innovative life science solutions. Science and technology parks in Greater Copenhagen, provide the ideal set-up for innovative life science companies, by promoting entrepreneurship through facilities and network etc.
10
8
6 4 3
9
7
5
7 Medeon Science Park
9 Ideon Science Park
Medeon Science Park is located in the heart of ‘Medicon Valley’ in the middle of the Öresund Region. It houses a cooperative and open meeting place for people active in life science. Medeon gather some of the biggest voices in life science to hold exciting lectures in close cooperation with Danish scientists. Medeon Science Park is a major player in the medical industry in Malmö and Medicon Valley – a research park offering a creative and inspiring environment for scientist enthusiasts and professionals.
8 Medicon Village
With an ideal location in Lund, Sweden, Ideon Science Park has taken huge steps towards more cooperation opportunities within life science companies. Ideon was the first science park to ever be established in Sweden and has become a front figure for future developments within ICT, life science, cleantech and medtech. Through close cooperation with Danish science organizations, Ideon Science Park has recently gathered top leaders from the pharmaceutical industry to create a future meeting space for researchers and entrepreneurs.
10 Krinova Science Park
Medicon Village is a Swedish life science research park offering lectures and meeting spaces in close cooperation with Danish researchers and companies. The park has more than 1,200 employees within its 100 organizations. In 2018/19 a great, purpose-built complex will stand ready as part of Medicon Village, providing more space for innovative researches and ideas. The first ever Swedish conference on advanced therapy will take place at Medicon Valley on 15th of March.
As a place for science enthusiasts, new research and creativity, Krinova has become one of the most popular science parks in Sweden, gathering people from all over the world. The science park incorporates debate-based lectures in their exciting program. Krinova is a platform and catalyzer for innovation and ideas circulating around food, environment and health.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
15
PROFILE
Ballerup steps up – new Open Innovation Lab to elevate its world class life science cluster Ballerup is to launch sale of land for life science and IT companies and start-ups. The aim is to form an even stronger life science cluster for the future, mixing life science with IT and tech. And a new Open Innovation Lab will play a key role.
T
he Municipality of Ballerup is home
The companies buying land here will not
to one of Denmark’s strongest life
be picked randomly but will be carefully
science clusters and is now gearing up for the future by inviting established life science and tech companies and start-ups to join them.
selected. “In this new industrial area, we will focus primarily on inviting life science companies to join us. Established
“The future is digital. The life science
companies, but also start-ups, in life
cluster here in Ballerup is keen to take
science, health tech and IT, that’ll be
that next leap forward towards a more
our target,” said Jette Rau, Director
Jesper Würtzen, Mayor of
Jette Rau, Director of
digital future and we want to facilitate
of Business Development at Business
Ballerup Municipality
Business Development
this. That’s why we’re now selling land for
Ballerup.
life science, tech companies and start-
The established companies in Ballerup are
ups to come and join us here,” said Jesper
increasingly talking about digitalization
Obviously, Ballerup will not be going
Würtzen, Mayor of Ballerup.
just as there is an increasing interest in
into business, but we will facilitate the
creating the foundation for the future,
companies, help them cooperate in new
where life science will be coupled with IT.
ways and we will create the right frames
Initially, Ballerup will sell six acres of land at the Kildedal industrial area, which borders the town of Maalov. In the second
“This spring we will begin to discuss
phase, a further 26 acres will be sold.
in more detail how we can do this.
16
for them,” Rau says.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
PROFILE
The Municipality of Ballerup, a suburb to Copenhagen Population: 48,231 Jobs: 45,000 – 34,500 private sector jobs and 10,500 public sector jobs Ballerup is part of a regional workforce. Every day, almost 35,000 commutes to Ballerup to work
Ballerup is the municipality in Denmark with:
Open Innovation Lab
“Forty years ago, there was nothing but
One of the ways the municipality of Ballerup will help facilitate the life science cluster will be through a new Open Innovation Lab, a place where corporates and start-ups can work closely together to find new solutions to the
fields here. Then came the oil crisis of the 1970’s, and the municipality of Ballerup
•
25,5% share; •
It’s the companies of the future we’re focusing on. That’s a clear strategy, both
The highest rate of IT employees in Denmark with 22% of the total
decided to focus on business. Not heavy industries, but knowledge companies.
Most foreign corporations with a
amount of jobs; •
The highest hourly rate at DKK 294;
(Source: The Municipality of Ballerup)
challenges we face in future such as
then and now,” Würtzen says.
lack of doctors. The Open Innovation
The Open Innovation Lab will include
The municipality of Ballerup has three
facilities such as a lab hotel co-working
main clusters: IT/Tech, Finance/Fintech
space, where lab producers can test new
and Life Science.
facilities too, facilities for Med Tech and
The Life Science cluster employs 4,900
Health Tech, auditorium and meeting
people in more than 30 corporations,
“Disruption is a buzzword these days
facilities, living facilities for short term
making it the second biggest life science
and not least in healthcare. With the
contracts and close relation to top
cluster in the country after Gladsaxe,
Open Innovation Lab, we can help our
universities and hospitals.
which is home to health care heavy
Lab will also be a place where start-ups can challenge corporates and extract tomorrow’s business and ways of dealing with growing healthcare issues.
companies work in the intersection of IT, tech, pharma and life science to come up with the solutions of tomorrow and perhaps take it global too,” says Jesper Würtzen. Ballerup’s life science cluster is home to more than 60 established life science
“Ballerup is perfectly positioned with short travelling distance to numerous
weighs Novo Nordisk and Novozymes (Source: Medicon Valley Alliance).
universities and hospitals and with an excellent infrastructure, such as airport, trains and busses,” says the Business Development director.
corporates, including large players such
“Ballerup is open for business, so don’t
as Novo Nordisk, Origio, LEO Pharma, GN
hesitate to get in contact,” she says.
and Pfizer. “But we want to make it attractive for start-ups too. We want to engage the large corporates, attract exciting start-ups, which can support what the corporates do, but also create new growth companies. That’s our aim,” says Rau. Developing the new business area in Ballerup is a project for the long term and even though the full picture is not drawn up yet, the endpoint is very clear. We are looking for partners that are interested in going in to this with us, both in design but also financing and building the project, says the mayor.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
17
INTERNATIONAL TALENTS
COPENHAGEN CAPACITY KICKS OFF CAMPAIGN TO ATTRACT LIFE SCIENCE TALENTS TO GREATER COPENHAGEN A newly launched international campaign will seek to attract the very best life science talents to the Greater Copenhagen region. Arranged by Copenhagen Capacity, the campaign involves six companies. By Karin Jensen Copenhagen Capacity started
Copenhagen Capacity is
mobilising potential passive
talents. In total, six companies
some 25 years ago with the
not a competitor to private
international jobseekers,
have signed up for the
aim to create growth in the
recruitment firms, nor is it
who have not yet considered
campaign, each with up to
region by attracting foreign
involved with industries,
working in Denmark,” said
three job postings.
investments. Today, it also
where there is sufficient
Nikolaj Lubanski.
helps companies recruiting
labour.
“We ended up with four
On February 28th,
categories: Regulatory Affairs,
“We’re an add-on, a
Copenhagen Capacity and
Quality Control/Quality
“Our focus areas are IT/Tech,
supplement to a company’s
Invest in Skåne launched an
Assurance, Engineers, and
Cleantech and Life Science,”
own recruitment efforts.
international campaign to
Laboratory Technicians,” said
said Nikolaj Lubanski, Talent
Companies typically recruit
help life science companies
Nikolaj Lubanski.
Director at Copenhagen
in the vicinity but where we
in the Greater Copenhagen
Capacity.
can make a difference is by
region attract international
international talents.
18
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | M A RC H 2018
INTERNATIONAL TALENTS
After the eight weeks,
for smaller and medium-
Michael Hallgren expects the
Once the campaign is over,
the companies will be
sized companies, cultural
cooperation with Copenhagen
Novo Nordisk Kalundborg
sent between two and ten
differences can be a barrier,”
Capacity will increase Novo
will evaluate the candidates
candidates, who have been
said Nikolaj Lubanski.
Nordisk Kalundborg’s profile
Copenhagen Capacity finds for
internationally.
them and compare them with
screened by Copenhagen Capacity.
Customised Messages
Novo Nordisk Kalundborg Although known throughout the world, Novo Nordisk’s
A media channel strategy was
Kalundborg production facility
also put together, specifically
still has problems attracting
targeting the talents on social
and retaining talents
media such as Facebook,
commuting from Copenhagen,
Twitter and Youtube.
who often prefer jobs in the
Messages are customised and
bigger cities.
serves to trigger the curiosity of the talents and make them want to know more about working and living in Greater Copenhagen.
“We also expect to get a broader field of candidates to choose from than usually, and
the almost 100 international candidates already employed at Novo Nordisk Kalundborg.
perhaps even a higher level of
“We have a clear expectation
quality among the potential
that the candidates that move
candidates,” said Michael
to Kalundborg, stay here,” said
Hallgren.
Michael Hallgren.
“We’re looking at alternative ways to recruit, including attracting international talents, and that’s why we decided to join up with
Messages focuses on
Copenhagen Capacity for
place branding, the life
this campaign,” said Michael
science cluster in Greater
Hallgren, Senior Vice
Copenhagen, and then the
President at Novo Nordisk
actual job.
Kalundborg.
So far, Copenhagen Capacity has run five campaigns, which has led to 23 employments in total. However, the exposure has been enormous with films and banners on social media being showed around 70 million times over the course of the campaigns. “It’s an enormous exposure
“We’re an add-on, a supplement to a company’s own recruitment efforts. ,” says Nikolaj Lubanski, Talent Director at Copenhagen Capacity.
and we really see this as a long-term investment. We’re planting a seed and create awareness about Greater Copenhagen,” said Nikolaj Lubanski. The talents being sought are coming from both within and outside of EU. “We look at countries where we can offer something in terms of wages and social conditions. Secondly, there must be a cultural match as well otherwise it’s too much hassle for the company. Not for the big companies, but
19
INTERNATIONAL TALENTS
From Greece with love Stavros Kalafatakis, Research Scientist, Fermentation Discovery team at FMC, is one international talent who found happiness in Denmark. Kalafatakis decided to leave his home country Greece in 2011 to do his Master’s and later Ph.D in a new country. “I wanted to go to a country which was quite developed and had low unemployment.
education programs are taught
pleased with his choice and
in English, not to mention
highlights a good social life
that unemployment was very
with friends and good working
low at that time,” said Stavros
conditions. Last summer he
Kalafatakis.
landed his first job after his
A strong welfare system, health care, paid holidays and a rich cultural life in Copenhagen also attracted Kalafatakis. “Also, the pictures looked nice and always sunny,” said Kalafatakis with a smile.
Denmark offered free tuition,
Now, seven years after his
and most of the higher
arrival, Stavros Kalafatakis is
Ph.D, as a research scientist with FMC, and is about to start a family with his soonto-be Danish wife. “I like it here, both personally and work-wise. It’s an excellent place to build a career and have a good lifework balance,” said Stavros Kalafatakis.
“I wanted to go to a country which was quite developed and had low unemployment." Stavros Kalafatakis, Research Scientist, Fermentation Discovery team at FMC
DO YOU HAVE THE RIGHT EXECUTIVE SEARCH PARTNER WITHIN TECHNOLOGY & LIFE SCIENCE? Best Talent is a Nordic Market Leading Search company and partner of the international Global Executive Search Organisation ENEX.
We have a solid knowledge of the market conditions and a very attractive executive network, in which we employ search strategies that attract highly qualified candidates.
Best Talent performs Executive Search across all functional areas within Engineering, Medical Device, Pharmaceutical, Biotechnology and Food Science. We have more than 15 years of experience in assessing talents skills and potential.
Please do not hesitate to contact Best Talent for further information on +45 4556 5300. Read more at www.besttalent.dk
NUMBER 1 PROVIDER OF HUMAN TALENT WITHIN TECHNOLOGY & SCIENCE
Best Talent · Rungstedvej 41 · DK-2970 Hørsholm · T: +45 4556 5300 · info@besttalent.dk · www.besttalent.dk Best Talent is member of Enex Global Executive Search Organisation and is represented worldwide in more than 40 countries.
2747 BestTalent_halvside_aarbog.indd 2
28/02/2018 20.34
PROFILE
Work in Denmark helps attract international candidates to Denmark As the official International recruitment unit under The Ministry of Employment, Work in Denmark facilitates contact between Danish companies and International candidates and communicate knowledge and experience to all interested parties. Work in Denmark provides international jobseekers and Danish employers with the information, guidance and tools necessary to find each other. It is a public employment service for highly qualified international candidates looking for a job in Denmark, and Danish companies searching for talented foreign candidates. Work in Denmark is part of the Danish Ministry of Employment and a member of the European Employment Service, EURES. The three Work in Denmark offices located in Copenhagen, Odense and Aarhus, offer a series of recruitment services to employers as well as information and guidance to international jobseekers. “Our services include job match, where we match the right candidates with the companies. Once the candidate has decided to move to Denmark, we help with the necessary registration, both before and after arrival here. We also participate in job fairs and help brand Denmark as an attractive place to work,” said Mette Wassmann, International Recruitment Consultant at Work in Denmark. Work in Denmark’s mission is to assist the thousands of well-educated foreigners who come to Denmark every year to live and work. Many are attracted by the opportunity to combine professional challenges, comfortable living conditions and family-friendly working hours. To meet the future need for well-qualified labour, Denmark needs to attract more
talented people from abroad. Many Danish private and public organisations are keen to recruit highly skilled international workers and make great effort to ensure that their international employees settle well into their new life in Denmark. “There’s a shortage of highly specialised candidates, primarily within engineering, IT and life science and this will only be more prevalent in future. This is a trend we see in the rest of the world too,” said Mette Wassman.
“This job fair is particularly important because MIT is one of the world’s leading technical universities, whose candidates count among the very best. Because it’s a European fair, the candidates we meet there have already decided to seek a career in Europe and our job is to make sure they look towards Denmark,” said Mette Wassmann. All services from Workindenmark are free of charge. For further information – please contact Mette Wassmann at Work in Denmark at mwa@workindenmark.dk
Work in Denmark participates in many different job fairs around Europe targeted at highly qualified candidates in areas where Denmark has a shortage. Work in Denmark has extensive experience in organising tailor-made recruitments abroad. In close co-operation with other EURES countries, Work in Denmark ensures a solution that meets the needs of both candidate and businesses. Work in Denmark can help promote vacancies, collect applications and provide preselected candidates. Some job fairs are general job fairs attracting candidates from many different areas while others are more targeted in relation to the demand in Denmark. This year, Work in Denmark is once again participating in the MIT European Career Fair in Boston, USA in a collaboration with the Confederation of Danish Industry, Copenhagen Capacity, the Technical University of Denmark and the University of Copenhagen. This provides Danish companies with the opportunity to work directly with one of the world’s leading technical universities to recruit some of the best-qualified candidates from the IT, life science and engineering sectors. The MIT European Career Fair takes place at Massachusetts Institute of Technology (MIT) in Boston and is especially tailored for candidates interested in working in Europe.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
21
REGULATORY COMPLIANCE
Finding the balance in regulatory compliance Life science companies have over the past two decades faced an increasing number of regulatory compliance requirements. Simultaneously, this rather conservative industry has generally been reluctant to fully implement new technologies for more efficient work flows. By Charlotte Strøm, MD PhD Journalist
T
ime to market has key priority in the life science industry. But on top of that price pressure and regulatory pressure apply, leaving the industry sitting on top a melting iceberg: Become more efficient or lose your business! Chief Consultant Mikkel Møller Rasmussen at The Danish Association of the Pharmaceutical Industry (Lif) thinks the matter is complex: -This is one of the fundamental areas of our industry, hence also one of the areas we and our members are very concerned with. Many
22
considerations can and must be weighed in relation to each other. Basically, patient safety is and will always be the most important, Mikkel Møller Rasmussen says, carrying on: -It’s true that the documentation requirements related to the regulatory compliance are growing. But I don’t find that strange at all because the trust in the system and the products are crucial, both for the patients and for the pharmaceutical companies. You will probably be able to find examples of regulatory compliance rules
that are overly implemented. Nevertheless, it is important to have rules that make it possible to rely on the products produced in our industry. After all, it is a different matter to produce medicines than it is to produce rye bread.
legacy of being risk aversive and too conservative to apply and specifically make optimal use of new IT systems and processes. In that way the regulatory compliance becomes a costly affair that does not truly add value to the business, says Klavs Esbjerg.
Klavs Esbjerg, CEO at Epista Life Science argues that some areas of the pharmaceutical industry would benefit from a leaner approach.
He points to the key findings of a recent market survey that was done within stakeholders of the Danish life science industry.
-The problem is that regulatory compliance is overly implemented, while the industry as a whole has a
-The industry faces a tough balance that overspending time and resources on regulatory compliance may
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
REGULATORY COMPLIANCE
put the companies out of business, while underspending may put them at risk of losing control of compliance. 51% of the respondents from life science companies responded that regulatory compliance and business requirements are seen as opposing forces in the company.
Lack of transparency and predictability The market survey uncovers a lack of transparency and predictability with the regulatory compliance area. This is seen locally within the company and centrally with the regulatory authorities. -Generally, the life science industry is extremely good at providing documentation, i.e. demonstrating to themselves and the outside world that they are in control. But along the way they failed to ask themselves how and what specific parts of the regulatory compliance that add value to the business, Klavs Esbjerg comments on the survey and carries on, -What we typically see is over-doing, over-engineering, and over-implementing best practice in a way that’s turning into malpractice, claiming that this is a regulatory requirement while in fact it is a misinterpretation of the intentions. But regulatory compliance is a matter of patient safety, how can that be a misinterpretation? ¬-True and this is certainly not an argument to let go of the standards when it comes to patient safety. But the issue
is that the crucial steps to ensure patient safety has been moved into every corner of the business and overly applied in a manner that no longer has any relevance to patient safety. To Chief Consultant at Lif, Mikkel Møller Rasmussen, this is also a matter of credibility. -This is an industry with many internal rules that were born centrally within EFPIA (The European Federation of Pharmaceutical Industries and Associations) for the majority and sanctioned locally by ENLI (Etisk Nævn for lægemiddelindustrien). The rules put in focus the advertising rules, the industry image - and thus the confidence that we act responsibly. There may be internal business rules that may appear "too much". But I think it is worthwhile to keep in mind that there may be more to it than that, arguments that you as an outsider may not know.
regulatory authorities. An example of that would be the e-application for marketing authorizations of medicinal products. It’s more than a decade ago that it was implemented, still ask yourself whether the use of paper documentation has actually decreased during that same period of time, Klavs Esbjerg argues. He stresses that the costs of bringing a medicinal product to the market is undergoing a disturbing development. -In the 80’ies the cost of bringing a new drug to the market was around 0.5 billion, today the estimated cost is 1.5 billon US dollars. It is not all due to better drugs. It reflects an overspending of compliance resources. Faced with the external pressure from pricing and reimbursement, the life
science industry need to start asking the question on how this can be balanced, he says and ends, -Currently the life science industry is aiming to run a marathon in record breaking times with massive overweight on its shoulders. The companies that have the courage to apply e.g. new IT technologies in order to become more efficient, who take advantage of cloud sourcing and furthermore have the trust and courage to challenge the regulators on moving into the 21st century, are the ones that will make it in the end.
Read more about the survey: http://www.epista.com/ compliance-maturity-2017
Updated IT systems and processes Regulatory authorities set out framework on the regulatory requirements. Is this a problem that lies with the hen or the egg? -In general, there is a fundamental fear in the life science industry of changing specific processes, e.g. applying a tool that would improve the work flow around patient reporting in clinical trial settings. They don’t know how it is going to come down with the
“There is a fundamental fear in the life science industry of changing specific processes, e.g. applying a tool that would improve the work flow,” says Klavs Esbjerg, CEO at Epista Life Science.
23
PERSONALIZED MEDICINE
Medical University of Vienna (MUW) to collaborate with bio.logis GIM in pharmacogenetics MUW will implement bio.logis Genetic Information Management Suite (GIMS) / platform for the automatic creation and online display of diagnostic reports and treatment recommendations / safety code card for patients. Source bio.logis Genetic Information Management GmbH
W
ithin the framework of U-PGx, an EU project for promoting the use of pharmacogenetic insights in healthcare, the Medical University of Vienna (MUW) will implement the Genetic Information Management Suite (GIMS) developed by bio.logis Genetic Information Management GmbH. The platform is the first of its kind to largely automatically translate genetic analysis results from laboratories into easily understood diagnostic reports, including the right treatment recommendations from the internationally renowned KNMP (the Royal Dutch Pharmacists Association). Here, the MUW uses the Diagnostic Report Module (GIMS.DRM) in combination with a QR-based safety code card, developed by MUW, for patients. This card is used to make patients’ personal analysis results accessible. There is still far more scope in medical practice to use pharmacogenetic insights. The
EU-funded project Ubiquitous Pharmacogenomics (U-PGx) would like to support this because pharmacogenetics enables important progress in personalized medicine. As a key partner of the U-PGx project, bio.logis GIM has implemented its Genetic Information Management Suite (GIMS) at selected university hospitals and institutions in various European countries, including the Medical University of Vienna. bio.logis and MUW have now agreed to offer the safety code card—an emergency card for patients, the size of a credit card—beyond the scope of the U-PGx project. A QR code printed on the card gives patients an easy and quick access to a web portal which provides dosing recommendations based on the patient´s genetic analysis. These recommendations will support the attending physician in prescribing the right medication in the right dosage.
“Within the framework of U-PGx, the bio.logis Genetic Information Management Suite enables us to automate and speed up the creation and delivery of easily understood genetic-diagnostic reports,” says Assoc.-Prof. Matthias Samwald, MUW, who is also one of the U-PGx project leaders. “We will offer the products jointly developed during our cooperation also outside of this project.” bio.logis GIMS works with pre-configured standardized expert knowledge. With the system’s Diagnostic Report Module (GIMS.DRM), creating a genetic-diagnostic report is done in a matter of seconds. An enormous time and cost saver, compared to traditional methods. The Delivery Module (GIMS.DM) can then be used by authorized physicians or the patients themselves to fetch these reports. The safety code card supplements the information for the patients. “Our expert team, consisting of experienced specialists in human genetics diagnostics,
biologists and IT professionals, has developed bio.logis GIMS—a software platform using special algorithms, workflows and modular components for creating genetic-diagnostics reports and making them available at the point of care in very short time,” emphasizes Prof. Daniela Steinberger, Medical Managing Director, bio.logis GIM. One of the most important considerations for bio.logis in every development is the security and protection of personal data. The system itself processes exclusively pseudonymized analysis data. Every communication channel is generally encrypted. This ensures that the allocation of analysis results to individuals can only be done by the responsible medical staff within the clinic. bio.logis complies with existing data security regulations including the EU-wide General Data Protection Regulation (GDPR), coming into force on May 25, 2018.
About bio.logis Genetic Information Management GmbH
24
bio.logis Genetic Information
(GIMS)” IT solution which, in the
in laboratories for automatically
tion systems as well as electronic
Management GmbH translates
process chain required for genetic
generating such expert content,
health records. For more infor-
genetic data into medically
diagnostics, focuses on the "last
and in hospitals with specific clini-
mation about our company and
leverageable information and
mile” from physician to patient
cal suggestions. The physician
our products, please visit https://
makes it available to physicians
by merging raw genetic data with
reports and recommended action
www.biologis.com/.
and patients. To that end, it has
clinically leverageable knowl-
generated by GIMS is delivered
developed a special “Genetic
edge for prompt application.
straight to the point of care via
Information Management Suite
GIMS supports physicians both
laboratory and physician informa-
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
DOOR SOLUTIONS
Door solutions for pharmaceutical industry Door System delivers durable door solutions, which follows the strict requirements regarding materials, hygiene and reliability in the pharmaceutical industry. Door System doors are developed specifically for maximum reliability, which is paramount in pharmaceutical companies, and for a top clinical production environment.
Pressure difference: 15 Pa Pharmaceutical companies create overpressure in production areas, for clinical reasons. This means a pressure difference in the doorway between two rooms. Door System has therefore designed the doors to function in surroundings with a pressure difference of up to 15 Pa.
Easy to clean Easy access to 100 % cleaning. Automatic controls encapsulated in stainless and water- proof boxes. No visible screws or fitting plugs. Interlock system between doors. Safety sensors on all automatic doors.
Your future service provider Elite Miljø provides specialized services for cleanroom businesses We service the biotech, healthcare and pharmaceutical industries as well as other cleanroom and controlled environment industries.
For further information on Door Systems or door solutions for the pharmaceutical industry or general inquiries contact Sales Manager Søren Rahbek, +45 42 14 52 02, e-mail sr@doorsystem.dk.
Elite Miljø offers you: • A proven success in cleanroom cleaning • Certified training, retraining, audits and consulting • Trained cleaning personnel on cleaning techniques in critical environments • Trained technicians on cleanroom protocol, safety, security, cleaning techniques, and client specific procedures • A comprehensive quality management system that is customized to your SOPs and other requirements • A proven cleanroom concept, integrated into a dedicated organization • Extensive experience with external and internal audits • Specialized systems that comply with GMP and ISO standards
Rådgivning og Konsulentbistand med høj faglighed og proces-orienteret tilgang inden for farma, biotek og medtek.
Projektledelse Validering
Kvalitetssikring Produktionssupport
– And comply with all GMP and ISO standards… Ring eller skriv for uforpligtende dialog:
Enter our website and learn more or contact us directly at +45 2835 4001
Kvalificering
V i mod tage r uop fordred e ansøgninge r
sales@aoge.as - Tlf. 31178232 elitemiljoe.dk/renrum
Andreasen & Elmgaard A/S, Generatorvej 8C, 2. TH, 2860 Søborg. www.aoge.as
OVERVIEW
BIOTECH pages 30-33
MEDTECH pages 35-37
PHARMA pages 38-40
CONTRACT RESEARCH ORGANISATIONS pages 42-45
CONTRACT MANUFACTURING ORGANISATIONS pages 48-49
BUSINESS SERVICE PROVIDERS pages 50-54
26
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
OVERVIEW
LABORATORY, MEDICAL & PHARMACEUTICAL EQUIPMENT pages 56-60
COMPANY INDEX pages 62-71
WHEN CHOOSING YOUR REGULATORY PARTNER IS A MATTER OF TRUST DONE RIGHT – FIRST TIME EVERY PROJECT AND EVERY CLIENT IS DIFFERENT A-consult group offers the whole palette of Regulatory Affairs, Quality and Vigilance. Our objective is to ensure that you get the best professionals every time. A-consult group offers solutions adapted to your timelines and your budget in compliance with local regulations. Learn more about our services online: www.a-consult.com
PROFILE
Efficient detectives hunting impurities in the pharma industry. When pharmaceutical production lines or QA (quality assurance) detect an irregularity in a medical product, a rapid, reliable identification and characterization is required. -Speed is often an issue. It is costly to halt e.g. a production line or withhold a batch due to irregularities, so we do our utmost to deliver analysis results and identification within these sometimes rather strict deadlines, Specialist Jacob Markussen from FORCE Technology explains. He is heading the team of specialists working with material and surface characterization at FORCE Technology, an authorized provider of technological services – a GTS entity. At FORCE Technology a characterization typically starts in the scanning electron microscope (SEM), which allows magnifications up to 1 million times. Further analyses may be undertaken in other microscopes such as the FTIR (Fourier Transform InfraRed spectroscopy) microscope along with a large number of other chemical analysis methods. But there is more to it than having the right technological equipment, Jacob Markussen stresses: -We have a team of specialists, who are highly competent and experienced within their own area, e.g. metals, plastics, organic material, minerals, composites etc. Identification is often more a matter of pattern recognition than the technical analysis itself. Recognizing from experience and expertise what the different irregularities typically resemble allows us to test and verify our findings rapidly to the benefit of our clients.
28
Once the irregularity has been identified and characterized the information goes back to the client. -The important information is obviously to find out what we are dealing with, and whether or not it impairs the safety and the quality of the product. Once that information has been established reliably, we typically assist in locating the source and cause of the contamination. It could be a metal, which can be traced back to a certain area of the production line, or a rubber material that are used only in certain sealings. Independent experts The skills as true detectives are also used when acting as independent experts in arguments about faulty deliveries. -Medtech or pharma companies often have deliveries from a range of sub-suppliers. In case of an irregularity, it can become quite crucial to find the source of the contamination to stop it and in order to get reimbursement, Jacob Markussen says and ends, -In general, the life science business work by very high standards, by having agile and thorough quality assurance systems in place that manage to capture even minute signs of contaminations. Our finest job at FORCE Technology is to help our clients make qualified decisions based on reliable knowledge and facts.
Facts about FORCE Technology •
FORCE Technology is a leading technological consultancy company. We offer consultancy and services within energy, oil and gas, the maritime sector, manufacturing, the service sector and infrastructure.
•
Provides in-depth knowledge about the surface of materials and products for the life science sector along with a series of other industries.
•
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
For more information please visit: http://FORCEtechnology.com
Conference on Big Data in Biotechnology and Biomedicine May 31 – June 1, 2018, Hotel Munkebjerg, Vejle, Denmark High throughput methods are constantly refined to enable large-scale investigation of complex biological systems. The basic scientific paradigm is to understand and predict the relation between architecture, structural information and function. The continuous and massive increase in DNA and protein sequence information and advances in quantitative experimental technologies in biology, represents an enormous potential for research of academic, industrial as well as biomedical value. The challenge remains how to get meaningful information out of this vast “ocean” of data information derived from a multitude of species including individual human beings. The conference will focus on the latest developments in creating, utilizing, handling and methods for analyzing Big Data in biotechnology and biomedicine including sessions on - Precision medicine - Statistical genetics - Single cell analysis - Systems biology in medicine and process biotechnology - Biological and genomic networks - Microbiomics - Best practice on handling and storage, safety and ethics Speakers accepted • • • • • • • • • •
Speakers invited
Armand Valsesia, Nestlé , CH Henrik Rindel Gudbergsen, IBM Nordic, DK Henrik Bjørn Nielsen, Clinical Microbiomics, DK Jens Nielsen, Chalmers, S José-Maria Gonzalez-Izarzugaza, DTU, DK Mads Albertsen, AAU, DK Markus Herrgard, NNF Biosustain, DK Mathias Uhlén, KTH, S Sandrine Muller, Massachusetts General Hospital and Broad Institute of MIT and Harvard, USA Thomas Senderovitz, Danish Medicine Agency, DK
• • • •
Chris Spencer, Welcome Trust, UK Lude Franke, University of Groningen, NL Matt Might, University of Alabama, USA Martin Hemberg, Sanger Institute, UK
The conference is organised in collaboration with Danish Society of Biochemistry and Molecular Biology and includes a poster session as well as a commercial exhibition of equipment, consumables and services to Danish biotechnology. Scientific Committee Ole Nørregaard Jensen, University of Southern Denmark Leif Schauser, Qiagen Jochen Förster, Carlsberg A/S Eric Paul Bennett, University of Copenhagen Leonor Rib, University of Copenhagen Lars Haastrup Pedersen, Aalborg University Deadline for poster abstracts and registration: April 10, 2018. For questions regarding participants registration, please contact Anne Dalgaard, The Danish Society of Engineers, IDA, at ada@ida.dk. Registration will open December 1, 2017 , see announcements at www.biokemi.org or www.ida.dk Participation fee: 3500 DKK ; reduced fee for students (Ph.D. and M.Sc.): 1800 DKK. M.Sc. student scholarships find info at www.synapse-connect.org
1
Svanholm.com DreamTeam!
BIOTECH
MS til offgas. OUR, CER og RQ
Online måling af levende celle densitet med kapacitans
Lineær OD sensor, stor range, der ikke forstyrres af bobler
Optisk Densitet (OD) med høj følsomhed
Physoxia Workstations. Optimalt arbejde med celler
“It takes a constant inflow of innovation to maintain a vibrant industry.” Martin Bonde, Chairman of the trade organization of the Danish biotech companies, DANSK BIOTEK, and
Lucullus PIMS software styrer alle fabrikater af fermentere. Numera automatisk prøveudtagningssystem sampler 24/7
CEO at the biotech company Vaccibody.
BIOTECH
FASTEST GROWING INDUSTRY The Danish biotech industry is constantly on the move, growing and getting stronger. Still, funding from the stock market appears to be challenging in Denmark whereas Sweden has a different IPO culture for small and midsize life science companies. By Charlotte Strøm, MD PhD Journalist
T
his biotech industry has
history for listing of small
I believe that a single-entry
companies that have been
so many good things
biotech on the Copenhagen
point to the political system
around for a decade or more
going on. It is the fastest
stock exchange. History drives
will be a major advantage for
and are still going strong,
growing industry in the coun-
the culture and the legacy
us.
mentioning Genmab, Bavarian
try, and the companies have a
that fertilizes the investing
series of very exciting research
environment, he says.
projects going on, says Martin Bonde, who is the Chairman of the trade organization of the Danish biotech companies, DANSK BIOTEK, and CEO at the biotech company Vaccibody. He continues,
ing the necessary investments
that the increased political
at the Copenhagen stock
commitment to the life science
exchange, some take their
industry as a major industrial
exits to the stock exchange in
and economic national growth
Sweden.
factor will gradually help the willingness to invest into Danish biotech companies into
are sold to foreign investors
the right direction. He points
and some perhaps a little too
to the intention of establish-
soon. Most often it unfortu-
ing a life science office at the
nately implies that the tech-
Ministry of Industry, Business,
nologies they represent and
and Financial Affairs as the
the jobs exit the country.
first step to start organizing
continuously risk aversive and perhaps conservative stock
and establishing and improving the industry’s conditions to operate.
market culture in Denmark as
-Until now we’ve had two-
a major obstacle.
three-four different ministries
-Clearly, we struggle as an industry without strong
stantly face challenges in rais-
Martin Bonde is anticipating
-Regrettably, some companies
Martin Bonde points to a
As the biotech companies con-
to address organizational matters of the industry with.
-Over the past few years
Nordic, Zealand Pharma, and recently in 2017 Orphazyme was publicly listed on the Danish stock exchange, hence going against the trend of taking the IPO to Stockholm.
Strategic investments in biotech and start-ups
almost all IPO’s among small
Martin Bonde stresses the
biotech companies have taken
importance of maintaining
place in Sweden, where there
a solid foundation of growth
is a different tradition and
and points to the venture
back-up also among private
capital as instrumental in that
investors. We seem to lack a
setting. Beyond that he high-
public market in Denmark that
lights a recently announced
allows for the best Danish bio-
investment made by the Novo
tech companies to raise money
Nordisk Foundation as major
here, Martin Bonde says.
highlight of the past year.
He does point out, however,
-In December 2017, the Novo
that by now, a number of
Foundation decided to invest
continuously growing biotech
in the establishment of a Bio-
companies have demonstrated
innovation Institute with the
the power of innovation, i.e.
primary purpose of promoting start-ups in the life sciences in Denmark.
"We seem to lack a public market in Denmark that allows for the best Danish biotech companies to raise money here"
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
The Bioinnovation Institute is a long-term initiative of 10 years and the Foundation has
31
BIOTECH
awarded a grant of DKK 392
-We hope that we can high-
-It takes a constant inflow
million to cover the 3-year
light Denmark as a strong
of innovation to maintain a
establishment phase. The
powerhouse in northern
vibrant industry. This initia-
institute is a Danish initia-
Europe for maturing research
tive aims at creating synergy
tive that has an international
and start-ups in the life
with the existing academic
perspective. It will be located
sciences so that Danish and
and general research envi-
at Copenhagen Bio Science
international investors will
ronments and the life science
Park (COBIS) in Copenhagen,
perceive the life sciences in
environment located in the
close to the universities.
Denmark as an attractive
area, Martin Bonde says, and
field for investment. This will
ends,
The Chairman of the Novo Nordisk Foundation, Scheibye puts it this way in the press release from the Novo Nordisk Foundation.
enable the solutions developed to benefit everyone and to create new companies and jobs in the long term.
-With that I set my hopes for a new year that can take off where the previous one ended.
"We struggle as an industry without strong history for listing of small biotech on the Copenhagen stock exchange. History drives the culture and the legacy that fertilizes the investing environment" Says Martin Bonde, Chairman of the trade organization of the Danish biotech companies, DANSK BIOTEK, and CEO at the biotech company Vaccibody.
HAR DU DEN RIGTIGE SEARCH PARTNER?
TO DENMARK??? Hvis vi skal bryste os lidt, er vi nogle af de bedste til at finde nye talenter inden for Technology og Science. Vi udfører Executive Search til Senior Executives og top level specialister worldwide til følgende brancher: • Pharmaceuticals • Biopharmaceuticals • Medical Devices & Diagnostics • Engineering & Technology • Consulting
• Biotechnology • Public Health & IT • Health Management • Veterinary Best Talents succes beror på stort kendskab til vores kunders krav og udfordringer – og vi ved, hvad der kræves i forhold til at tiltrække de rette talenter.
udviklingen, og dermed risikerer Danmark, at
det rammer vores vækst, hvis dette fortsætter. For at kunne tiltrække top talent fra udlandet har vi etableret os i et internationalt search samarbejde, der er repræsenteret i mere end 40 forskellige lande – heriblandt USA, Kina, Indien og Australien. skerordninger, men samtidig må man også som virksomhed være klar til at yde en ekstra indsats, når det gælder integration af det nye talent.
NUMBER 1 PROVIDER OF HUMAN TALENT WITHIN TECHNOLOGY & SCIENCE
Best Talent ·Rungstedvej 41· DK-2970 Hørsholm · T: +45 4556 5300 · info@besttalent.dk · www.besttalent.dk Best Talent is partner in ENEX Global Executive Search Organisation and is represented worldwide in more than 40 countries.
• Traceability, validated processes and documentation based on innovative cleanroom technology. • Specializes in on-site training of operators in correct use of cleanroom clothes and cleaning articles. • Preferred partner of unique cleanroom solutions in accordance to ISO and GMP compliance.
Get a sneak peek inside DFD CLEANROOM. Book a meeting: P: 040 65 66 500 (SE)/44 22 55 60 (DK) E: crmar@dfd.dk
Copyright © DFD0218029
EXPERIENCE THE MOST ADVANCED CLEANROOM LAUNDRY IN SCANDINAVIA
QUALITY PAYS Door System develops and manufactures door and gate solutions of the highest quality. This also means that our solutions are not always the cheapest on the market. But a high degree of operational reliability, great energy savings and low maintenance costs make our doors a very sound investment in terms of the overall operational life of the doors.
Manufactured in Denmark
We develop and manufacture all doors and gates at our factory in the town of Hasselager. Benefiting from many years of experience, a wealth of knowledge and insight, our staff is one of the most important reasons for our high quality. Our fitters are based all over the country and we offer full-scale service agreements.
Call us and get a quote today!
Tel: +45 8692 1171
· www.doorsystem.dk
INNOVATIVE SOLUTIONS for PHARMA, BIOTECH, MEDTECH & INGREDIENTS
I N N O V A T I V E S O L U T IHUMAN O NDISEASE S fMODELS or PHARMA, In the Forefront of Stem Cell and Immune Models. Our human DISEASE MODELS HUMAN DISEASE MODELS B I O T E C H , M E D T E C HHUMAN & I N G R ED IcellEModels. N TOurSand disease models cover pluripotent technology gene In the Forefront of Stem Cell and stem Immune human
DRUG FORMULATION & CHARACTERIZATION DRUG FORMULATION & CHARACTERIZATION
From Active Compound to Administration. Bioneer:FARMA’s From Active Compound to Administration. Bioneer:FARMA’s DRUG FORMULATION CHARACTERIZATION DRUG FORMULATION &&CHARACTERIZATION pharmaceutical services are dedicated to small molecules, pharmaceutical services are dedicated to small molecules, From Active Compound Administration. Bioneer:FARMA’s biologicsto ingredients. From Active Compound toand Administration. Bioneer:FARMA’s biologics and ingredients. pharmaceutical services are dedicated to small molecules, pharmaceutical services are dedicated to small molecules, RECOMBINANT PROTEINS biologics and ingredients. From Process Development to Purified Product. Production, biologics and ingredients.
DRUG FORMULATION &andCHARACTERIZATION RECOMBINANT PROTEINS purification characterization of recombinant proteins using From Compound to Administration. Bioneer:FARMA’s FromActive Process Development to Purified Product. Production, RECOMBINANT PROTEINS RECOMBINANT PROTEINS pharmaceutical services are dedicated to small molecules, purification and characterization of recombinant proteins using From Process Development to Purified Product. Production, From Process Development Purified Product. Production, biologics and and ingredients. prokaryotic eukaryotic to gene expression systems. purification and characterization of recombinant proteins using purification and characterization of recombinant proteins using prokaryotic and eukaryotic gene expression systems. prokaryotic and eukaryotic gene expression systems. RECOMBINANT PROTEINS prokaryotic and eukaryotic gene expression systems.
HUMAN DISEASE MODELS
In the Forefront of Stem Cell and Immune Models. Our human disease models cover pluripotent stem cell technology and gene editing as well as in vitro immunoregulatory assays.
In the Forefront of Cell and Immune Models. human editing well as in Stem vitro immunoregulatory assays. Our disease as models cover pluripotent stem cell technology and gene stem cell technology and gene editing as well as in vitro immunoregulatory assays. From editing Single Cell as to Complex Histology as well as an RNA in situ well as in vitro immunoregulatory assays. disease models & cover pluripotent MOLECULAR HISTOLOGY DETECTION
HUMAN DISEASE MODELS MOLECULAR HISTOLOGY & DETECTION
Detection Specialization. Identification, validation, quantification and documentation of disease relevant In theSingle Forefront of Complex Stem Cell and Immune Our in human From Cell to Histology as wellModels. as an RNA situ biomarkers. Combined IHC and ISH service.
MOLECULAR HISTOLOGY & DETECTION MOLECULAR HISTOLOGY & DETECTION disease models cover pluripotent stemvalidation, cell technology and gene Detection Specialization. Identification,
From Single Cell to Complex Histology as well as an RNA in situ From Single Cell Histology as well as an RNA in situ editing as well asto inComplex vitro immunoregulatory assays. quantification and documentation of disease relevant Detection Specialization. Identification, validation, Detection Specialization. Identification, validation, biomarkers. Combined IHC and ISH service. quantification and documentation of disease relevant quantification and documentation of disease relevant MOLECULAR HISTOLOGY DETECTION biomarkers. Combined IHC and&ISH service. Bioneer A/S Combined ISH service. Kogle Allé 2 biomarkers. t +45 45 16 04 44 IHC eand info@bioneer.dk From Process Development to Purified Product. Production, From Singlef +45 Cell to04Complex DK- 2970 Hørsholm 45 16 55 w Histology www.bioneer.dkas well as an RNA in situ purification and characterization of recombinant proteins using Detection Specialization. Identification, validation, prokaryotic and eukaryotic gene expression systems. quantification and documentation of disease relevant biomarkers. Combined IHC and ISH service. Bioneer A/S Kogle Allé 2 Bioneer A/S DK2970 A/S Hørsholm Bioneer Kogle Allé 2 Kogle AlléHørsholm 2 DK2970 DK- 2970 Hørsholm
Bioneer A/S Kogle Allé 2
t +45 45 16 04 44 f +45 45 16 04 55 t +45 45 16 04 44 +4545 4516160404 f t+45 5544 f +45 45 16 04 55
t +45 45 16 04 44
e info@bioneer.dk w www.bioneer.dk e info@bioneer.dk info@bioneer.dk w ewww.bioneer.dk w www.bioneer.dk
e
info@bioneer.dk
MEDTECH
“This recommendation demonstrates the acknowledgement of a strong regulatory authority with the right competences and enough hands to meet the need of the applicants.� Peter Huntley, CEO at Medicoindustrien
MEDTECH
HIGH EXPECTATIONS OF THE GOVERNMENT’S LIFE SCIENCE GROWTH PLAN By Charlotte Strøm, MD PhD Journalist
I
n 2017, Medicoindustrien,
innovation, and growth.
Life Science Growth Team’s
the Danish medtech trade
CEO at Medicoindustrien,
recommendations that were
organization published a
Peter Huntley stresses that
presented in 2017.
booklet of industry specific
Danish medtech industry is
statistics. The numbers
vibrant and productive. Still,
demonstrate a strong position
he is enthusiastic about the
in terms of export, jobs,
political responsiveness to the
Stronger regulatory focus On the list of recommendations from the
-The initiatives that have
Life Science Growth Team
been announced based on the
was a strengthening of the
recommendations from the
position of the Danish Medical
Life Science Growth Team are
Agency.
promising. And by far this stands out as a highlight of 2017, Peter Huntley says.
-This recommendation demonstrates the acknowledgement of a strong
He points specifically to the
regulatory authority with the
increased political attention
right competences and enough
on the life science industry
hands to meet the need of the
with a life science growth
applicants, Peter Huntley says
plan, along with more
and continues,
general considerations and actions that hopefully result in optimized conditions for continued growth, not only within medtech – but overall in biotech and pharma as well.
-It is no secret that the medtech industry is challenged seriously by the increased regulatory requirements. We do support the necessity for clinical documentation and we
CEO at Medicoindustrien, Peter Huntley, has high expectations to the increased political focus on life science growth.
believe that it will give us better products of higher quality. However, it is a major challenge for our members that the capacity on notified bodies appointed to assess the clinical documentation does not meet the demands. There is a transition period that runs through 2020 for medtech equipment and through 2022 for diagnostic tests for the companies to have their products recertified.
MEDTECH
"It is no secret that the medtech industry is challenged seriously by the increased regulatory requirements. We do support the necessity for clinical documentation and we believe that it will give us better products of higher quality."
-I fear that the lacking
-Many of the medtech
Coming back to the increasing
within the industry in order
capacity will in fact make
companies spark from
regulatory demands, he also
to learn more about how to
some companies refrain from
engineering entrepreneurship.
sees some downsides to the
document the impact of the
re-certifying some products
Characteristically, they are far
‘upbringing’ and traditions of
products in patients, Peter
and if that turns out to be the
from patient-related activities
the industry.
Huntley says and concludes,
case, the Danish healthcare
and the turnover of products
system no longer has access to
is much higher than in pharma
-Clearly, as an engineer,
-Register-based research is an
these products.
or biotech for that matter. The
you don’t reflect a lot about
area of key interest to us. We
clinical documentation.
have no tradition of making
You have your mind set on
use of these type of data,
different matters related to
but we are keen on looking
the technology. So, we need to
into what opportunities and
improve our skills overall
learnings we can draw from it.
Innovation-driven industry
good thing about this type of environment is that it is
The industry has a legacy of
highly attractive to venture
innovative start-ups, which
capital and investors, Peter
tends to affect the culture and
Huntley says.
the mindset of the companies.
Gammadata | Your partner for bioimaging Providing microscopy solutions for: Fluorescence 2-photon Raman SEM, CLEM & AFM Anti-vibration tables Image courtesy of: M.J Mourik, LUMC Leiden, The Netherlands
+46 18 566 800
info@gammadata.se
www.gammadata.se
PHARMA
“It is worthwhile noting that clinical trial activity eases the access of innovative medicines for patients, educates the health care professionals, and altogether adds value to the Danish health care system.� Henrik Vestergaard, Deputy Director at Lif
PHARMA
STRONG POLITICAL LIFE SCIENCE FOCUS IS A MAJOR BREAKTHROUGH The Danish Association of the Pharmaceutical Industry (Lif) looks back at 2017, pleased with politicians who finally acknowledged the significance of the industry. Another breakthrough, although on the negative side from Lif’s perspective, was the establishment of a prioritization institute on medicines. By Charlotte Strøm, MD PhD Journalist
L
ike other key stakeholders
He is positive that the
attempt to refrain patients
the negative aspects of the
in the life science
initiative of a life science
from gaining access to
Danish Medicines Council’s
industry, the Deputy Director
office will maintain the
medicines, Henrik Vestergaard
work.
at Lif, Henrik Vestergaard,
political focus to a much
says.
seconds the enthusiasm
larger extent than what has
about the governmental
been the case so far.
-The council is hardly up
He points to the council’s
and running, due to the new
alleged power to omit certain
and increased standards of
Prioritization institute
medicines from the standard
impartiality to the experts
recommendations of the
Henrik Vestergaard is
of care national programmes
that are going to be running
Life Science Growth Team in
considerably more subdued
based on the costs alone,
the assessments. By all
March 2017.
on the establishment of the
refraining from making use
means, impartiality is highly
plan to issue a growth plan for life science based on the
-Clearly this is a breakthrough, because this is the first time ever that the politicians acknowledge the potential of this industry that goes beyond merely having a strategy for medicines, Henrik Vestergaard says.
prioritization institute, The Danish Medicines Council.
of standardized measures like quality adjusted life year
important, but so is clinical experience, and we fear that the experts who live up to the
The purpose of the council
(QALY) in their assessments of
is to assess new hospital
new medicines.
medicines and several
Henrik Vestergaard admits,
experienced clinical experts in
however, that Lif does not – in
the therapeutic field. But we
January 2018 – have a series of
still have to wait and see how
negative cases to demonstrate
this goes.
medicines within the same therapeutic area. -We see this as a coordinated
high demands of impartiality may not be the most
"The council is hardly up and running, due to the new and increased standards of impartiality to the experts that are going to be running the assessments."
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
39
PHARMA
Access to health care data By May 2018 the EU law on General Data Protection Regulation will come into action. Henrik Vestergaard stresses that this will have Lif’s continued focus in the coming year. -It has been and is continuously being discussed intensely who should have access to the citizens’ health care data. The pharmaceutical industry is obviously highly interested in health care data for research purposes. But it is immensely important
to underline that while the research is looking for patterns within large populations, individual events and personal pieces of information are of no interest whatsoever, Henrik Vestergaard notes, carrying on: -At Lif we have a hard time seeing how the society as a whole can continuously make progress without maintaining access to and allowing researchers to gain knowledge and improved understanding from health care data. This is not an issue for our members only, it is
Deputy Director at Lif, Henrik Vestergaard, sees the political receipt of the Life Science Growth Team’s recommendations as a breakthrough in 2017.
also potentially obstructing epidemiological research in academia. Hence, we will do what we can to help kill the myths and misunderstandings of this topic.
Working on NEXT 2.0 Henrik Vestergaard points to the successful NEXT private-public partnership on attracting early clinical research to Denmark. But the dream scenario is that big pharma’s clinical development programmes will find their way back to Denmark, including the largescale phase 3 trials. -Currently big pharma is having a hard time seeing that Denmark should stay on the map of attractive clinical trial sites. We hope to be able to change that over time in collaboration with the Danish Regions, he says and ends, -It is worthwhile noting that clinical trial activity eases the access of innovative medicines for patients, educates the health care professionals, and altogether adds value to the Danish health care system.
40
The broadest collection of QC microorganism products for
GROWTH PROMOTION TESTING
Choose from 4 unique products that meet your specific needs – all designed to deliver 10-100 CFU as required by the USP/Ph. Eur./JP.
SERVICES FOR THE PHARMACEUTICAL INDUSTRY » IT/MES/MIS » AUTOMATION » VALIDATION » OPTIMIZATION » PROJECT MANAGEMENT
+45 48 25 10 00 info@angroup.dk www.angroup.dk
CONTACT AN GROUP
CRO’s
Contract Research Organisations
Last year we asked the Scandinavian pharmaceutical- and biotechnology groups what they primarily considered when hiring a CRO for a clinical study. One of the most repeated answers was local presence, which a lot of the CRO’s are aware of, and expansion cross Scandinavian borders is a common trend.
CRO’S
ESTABLISHING LOCAL PRESENCE IN NORDIC COUNTRIES Scandinavian CRO, the Uppsala-based Swedish CRO, plans to double in size in five years and its goal is to become a leading Nordic CRO. Part of the strategy is to establish local presence in the other Nordic countries. Denmark, it believes, is one of the most interesting areas in life science right now. By Karin Jensen The Swedish CRO,
The goal is to become a
other Nordic countries with
streng thening the life
Scandinavian CRO (SCRO),
leading Nordic CRO and
local presence in Denmark,
science in Denmark. The
has just embarked on a new
to expand further in the
Nor way and Finland and
ambition of making clinical
grow th strateg y, which will
region and the first step
will be recruiting additional
trials available for more
see the group double in size
will be to double in size
staff to join the team.
patients, and aims for
in the coming years.
over the next five years.
“During the past ten years
“Today, we’re
Greater Copenhagen Life
we have built a healthy,
approximately 25 employees
Science cluster, is an area
sustainable and successful
in Sweden and Nor way
where SCRO has high
company. We have reached
covering the Nordic market
expectations.
the goals we set up and
and with revenue of 27
now it’s time to take the
million SEK,” said Ulrika
next step in our journey,”
Hammarström Lüllmaa.
said Ulrika Hammarström Lüllmaa, CEO at SCRO.
Denmark, and the
“Denmark, and
attracting clinical trials to the area, is of course a key factor for us to invest,” said Ulrika Hammarström Lüllmaa.
Need for a “smaller” CRO
Copenhagen, is one of the
SCRO’s new strateg y is
most interesting areas
based on a thorough market
SCRO is also currently in
right now with the many
analysis, which identified
the process of expanding to
concrete initiatives for
the need from the life
“Today, we’re approximately 25 employees in Sweden and Norway covering the Nordic market and with revenue of 27 million SEK,” Ulrika Hammarström Lüllmaa, CEO at SCRO
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
43
CRO’S
"Our USP is HOW you do it! We have developed a unique business climate in our company where skills such as communication and team work it highly prioritised. Business is done between people with people." Ulrika Hammarström Lüllmaa, CEO at SCRO
science industr y for a “smaller” CRO with more f lexible and tailor-made solutions and partnerships. “One of our streng ths is that we understand our clients’ day to day work and the challenges of resources and time frames they need to tackle. Time is money and you need to move fast with quality,” said Ulrika Hammarström Lüllmaa. Lüllmaa said another trend it is targeting is the Medtech industr y, which is growing and with more and more MedTech companies in urgent need of assistance to keep up with the new EU legislation that comes into force in 2020. “We have adopted all our standards and routines and have broad competence within the MedTech area,” the CEO said. Quality and competence are obvious key factors for a CRO,
44
CRO’S
according to Lüllmaa,
SCRO has developed a
of working,” said Ulrika
who believes that with a
Project Model, or Project
Hammarström Lüllmaa.
more digitalised world,
Culture, which includes a
spinning faster and faster,
framework of processes for
the personal meeting and
target settings, timing,
the understanding for each
risk management, quality
other's day to day work gets
assurance, documentation,
more and more important.
resources, budget,
“Our USP is HOW you do it! We have developed a
leadership and team
She said that in her experience, the larger CRO’s make the clinical trials more complex and less efficient with large systems and heav y administration. “One responsibility we have
building.
unique business climate in
“It gives us and our clients
our company where skills
an efficient and modern
such as communication
way of setting the purpose
and team work it highly
and goal for each project.
prioritised. Business is
It is important to stress
done between people with
that the model is NOT a
people. You must not forget
system that comes with
that,” stressed Ulrika
more administration but
Hammarström Lüllmaa.
builds an efficient way
as a CRO, is to facilitate for clinical sites and investigators to participate in clinical trials, not to overload them with administrative work,” the CEO emphasised.
Building a robust bridge? Clinical research is like building robust bridges. It is a question of expertise, experience & trust We can support your clinical development at any stage. From design of Phase I to final report of Phase IV studies Larix is a full-service clinical CRO providing high quality services to the biotech, pharmaceutical and medtech industries
To Earn Trust-Make Difference A+ Science is a complete clinical service CRO with focus on customer satisfaction. We have experience of services within clinical trials since 1997. Contact us to learn more about our services. A+ Science AB, www.a-plusscience.com
We offer insourcing of professionals and full service solutions with offices in Denmark, Sweden, Norway and Finland. Contact us today for a meeting to discuss your needs
Larix A/S Lyskær 8b • DK-2730 Herlev • Denmark P: +45 7027 2221 • E: info@larixcro.com www.larixcro.com
Communication - Proactivity - Quality on Time
Luntmakargatan 22, SE-111 37 Stockholm
PROFILE
LINK Medical Research strengthens its focus on Real World Evidence (RWE) LINK Medical Research has recently established the LINK Medical RWE department, which will see a further strengthening of the CRO’s focus on Real World Evidence (RWE). LINK Medical now offers a full palette of services for the pharmaceutical and medical device industry, but it stays true to its core values, which has been at the heart of the company since the beginning. LINK Medical Research is a Scandinavian
pharmaceutical groups have increasingly
which may require large subsidies from
full-service Contract Research
tested their drugs outside clinical trials
the state. However, the benefits of that
Organisation (CRO), offering project
and secured large amounts of patient
drug may be even bigger and could save
management and product development
data, which can help provide a bigger and
costs for society in the longer term.
services for the pharmaceutical and
fuller picture of how a drug works in real
medical device industry. At the beginning
life.
of 2018, its new LINK Medical RWE department opened.
“A drug for Parkinson’s disease, for example, is very expensive and will
LINK Medical RWE collects these data
require large subsidies. But the drug may
from various registers and provides
also help the patient to be more self-
“RWE is growing fast and is becoming
analysis for the pharmaceutical
reliant so that he or she can stay at home
more and more popular, especially among
companies.
for a longer time instead of going to a
“With a RWE analysis we can see how a
nursing home. The RWE analysis can help
drug works in the real world, for example
determine those benefits,” said Marianne
in populations not studied in the clinical
Holst, General Manager LINK Medical
The new RWE department, headed by Dr.
trial or by comparing it to a competing
Denmark.
Yngve Mikkelsen, will create value for
drug. An RWE analysis can also help
customers through secondary analysis
determine what the economic benefits are
Medical Device
of observational data from health care.
to society,” said Jan Hellqvist.
big pharmaceutical groups,” said Jan Hellqvist, General Manager LINK Medical Sweden.
Before a drug is being approved by health authorities, it has been through years of clinical trials. However, in recent years
An analysis on health benefits to society can for example be a very expensive drug,
Further to offering a full palette of traditional CRO services, LINK Medical also has a separate Medical Device department, with skilled and experienced
LINK Medical’s customers are mostly small and medium sized pharmaceutical and medical device companies and customer satisfaction is another key value for the group.
46
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
PROFILE
staff to take care of areas such as
CRO in Europe, not the largest.
regulatory requirements, documentation and risk management.
“Our values are our hobby horse. The focus is not on creating profit but on
“The regulatory process for medical
reputation, credibility, quality and
devices is becoming more and more
putting people first. Then everything else
similar to the rigorous regulatory process
will follow.”
for pharma and the requirements needed to get an authority approval are getting higher and higher too,” said Jan Hellqvist.
“Personal values too, such as keeping our word and delivering on time. It might sound a bit old-fashioned, but I believe
Jan Hellqvist, General
Marianne Holst, General
Manager LINK Medical
Manager LINK Medical
Sweden
Denmark
Regulatory requirements range from the
it’s our strength and probably why we
different phases in product development,
have such a low turnover of employees of
such as evaluation of CE classification,
less than 5%. I guess we’re very good in
documentation and clinical evaluation
recruiting the right people and holding on
report and interaction with Notified Body.
to them,” said Marianne Holst.
“We also offer Medical Writing, both
LINK Medical’s customers are mostly
business and has seen the company grow
within pharmaceuticals and medical
small and medium sized pharmaceutical
steadily over the years.
devices, and we have skilled people in
and medical device companies and
Denmark, Norway and Sweden dedicated
customer satisfaction is another key value
to this. In addition, we have hired some
for the group.
very skilled people in recent years to help our clients with for example quality systems and quality assurance,” said Marianne Holst.
LINK Medical’s values coupled with its extensive palette of services being offered to customers, provides for a healthy
“A lot of CRO’s have crumbled over the years but LINK Medical has managed to grow, even during the financial
“Our customer retention rate is above
crisis. It means a lot for both employees
70%, which is very unique in this industry.
and customers that we have a stable
We work with lots of small and medium-
economy,” said Marianne Holst.
sized companies and because of our
People and Values
level of experience, we’re in a position to
Founded 22 years ago in Norway by Dr. Ola Gudmundsen, LINK Medical is now present in Norway, Sweden, Denmark and Germany and employs 120 people. Ola
provide strategic advice to our customers. A CRO with predominantly junior staff cannot give the same level of advice” said Jan Hellqvist.
Gudmundsen’s goal was to create the best
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
47
CMO’s
Contract Manufacturing Organisations
"The development is going faster and faster and you have to be part of that otherwise you’ll be left behind,” Flemming Jensen, managing director at HB Medical
CMO’S
DISRUPTION HITS THE CMO MARKET – HB MEDICAL HAS THE ANSWER TO FUTURE GROWTH Danish Contract Manufacturing Organisations (CMO’s) are under pressure. Prices are low and competition tough, not least from Eastern European and Asian players. But HB Medical has found the answer – investments in full-automatic production. By Karin Jensen
D
isruption is a buzz word
to pay slightly more for a
The investments in the
Before making the
in many industries
Danish CMO, which are known
automated production is
investments in
and the CMO industry is no
for their quality, according to
a one-off investment and
automatisation, HB Medical
exception. Automatisation and
Flemming Jensen.
the management of HB
examined the entire
Medical sees a fast return on
production line to find
investments.
out where it could replace
robotics will see the industry change in coming years and the Danish CMO, HB Medical, has prepared for the future with investments in a new fully automated production. “This is our response to the high Danish wages. As a CMO, we’re not allowed to charge high prices, so we’re up against rather
“To be able to have “Made in Denmark” printed on their products is regarded as positive, and this speaks for slightly higher prices,” he said.
Danish CMO landscape will change The Danish CMO industry
Many international CMO’s in the US, Europe and
is dominated by a few, large
significantly higher than
players but the competitive
those in Eastern Europe and
landscape is likely to change
Asia, which makes it difficult
in years to come because many
to compete on equal terms.
CMO’s have not seen the way
“Automatisation is an
the world is moving, and the
international trend and it’s
way technology is changing
happening everywhere. The
the game.
development is going faster
“The investments we’ve made
competition. Our answer
in automated production is
is automatisation,” said
our chance. We’re nearly there
Flemming Jensen, managing
with certifications of these
“Disruption is just at the
director at HB Medical.
new standards,” said Lars
beginning. It’s a process that
Ibsen, head of production at
will continue in coming years.
HB Medical.
The industry will change
competition especially comes
example filling bottles.
However, Danish wages are
tough international price
International price
human hands with robots, for
from Eastern European and
“We expect to land new
Asian players, which can offer
customers and then,
significantly lower prices than
hopefully, the result will
their Danish peers. However,
be strong growth in the
some customers are prepared
business,” he added.
Asia are also investing in automatisation and robotics these days.
and faster and you have to be part of that otherwise you’ll be left behind,” said Lars Ibsen.
because automatisation is
“I expect several Danish
a general feature, which all
CMO’s will be left behind
industries will experience. Old
because they haven’t made
fashioned manual production
the right investments,” said
is just not sustainable,” said
Flemming Jensen.
Flemming Jensen.
“Disruption is just at the beginning. It’s a process that will continue in coming years. The industry will change because automatisation is a general feature, which all industries will experience.”
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
49
BUSINESS SERVICE PROVIDERS
EU GENERAL DATA PROTECTION RULES WILL TAKE DIRECT EFFECT THE 25TH OF MAY 2018 Edited by Arne Jensen
T
he EU General Data Protection Rules (GDPR) entered into force in May 2016 and will take direct effect in all member states from 25 May 2018. The GDPR will substitute the rules of Directive 95/46/ EC from 1995 and the Danish Act on Processing of Personal Data from 2011 and will significantly affect data controllers and data processors in the life sciences sector. Collection, analysis and transfer of sensitive personal data are vital for the life sciences industry to be able to develop and supply safe and effective medical products and devices. The GPDR is likely to significantly increase the burden of compliance and will be a challenge to pharmaceutical companies, clinical research
50
organisations, laboratories, sponsors and statisticians etc.
describe personal data flows through the entire life cycle
Implementation of the GDPR requires planning and reflection and 25 May 2018, is just around the corner.
- clarify whether you are data controller and/or data processor
How to ensure compliance with GDPR The best way to get started is to conduct a high level risk analysis to identify the categories of personal data processed by the company itself or via subcontractors and the areas where a DPIA is needed. A DPIA must cover all relevant business processes and should also include a gap analysis to identify noncompliance with the GPDR rules. Analyse your business processes and IT infrastructure in order to: - create a general view of and
- integrate the requirements of the GDPR into relevant business processes and IT infrastructure and when purchasing new IT systems (”privacy by design and by default”) - establish necessary structures, allocate roles and prioritise the tasks. Focus on the following key issues: - management and employees buy-in and training – create a culture of risk awareness and respect for personal data through entire life cycle - policy framework - create and implement
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
- IT systems and information technology – ensure robust security such as updated antivirus, antispam and firewalls and regular security code peer review - physical environment – create effective entry control systems, video surveillance and clean desk policies - incident detection and response – conduct regular data application inventories and restore availability and access in a timely manner. The GDPR is perhaps the most important EU legislation in many decades for the industry. However, if handled right implementation of the GDPR could be an opportunity to streamline and improve business processes and a strategic tool and competitive element.
BREXIT
CONSEQUENCES OF BREXIT! Naturally there will be consequences for the United Kingdom, but certainly also for the remaining Member States who will lose a significant member of the Community. Edited by Arne Jensen
F
ollowing BREXIT, life
to the EU/EEA will be met
science companies are
with a number of important
now experiencing the first
regulatory requirements. This
consequences. The impact
applies among other things to
has varying degrees, both for
applications for, or the transfer
pharmaceutical manufacturers
of a marketing authorisation for
and manufacturers of medical
an EU/EEA country, as well as to
equipment established in the
documentation that the products
United Kingdom, as well as those
live up to EU standards and quality
companies in the industry that
requirements.
conduct research and development as well as maintain production in the United Kingdom.
In this way, BREXIT has led to a flurry of questions to the European Medicines Agency (EMA), and in
A relatively simple example
its response, the EMA published an
consists of the many contracts (e.g.
opinion concerning the immediate
concerning case files, licensing or
consequences of BREXIT for
distribution), which parties have
holders of centrally authorised
concluded, where it is stated that
medicinal products.
obligations of the contract/rights apply to the territory designated as the "EU" or its equivalent.
Marketing authorisation after BREXIT
Companies should as soon as
Marketing authorisations
possible in each case deal with
for human and veterinary
business-critical contracts so that
medicinal products issued by
there is clarity. Perhaps it would
the EU Commission on the basis
also not be a bad idea to consider
of an EMA approval are valid
whether it would be advantageous
throughout the EU. The marketing
to move production/research and
authorisation is as a starting point
development activities from, or
valid for five years but may be
even to the United Kingdom.
extended.
The immediate consequence
The holder of the marketing
of BREXIT is that the United
authorisation (MAH) for a
Kingdom from late March, 2019,
medicinal product for both human
will no longer be subject to EU
and veterinary use, must be
legislation, and the country will
established in an EU/EEA country.
thereby acquire third country
BREXIT therefore means that
status, such as e.g. Switzerland
holders of centrally authorised
or the USA. The effect will be,
medicinal products, where the
that pharmaceutical substances
MAH has been established in the
and finished medicinal products
United Kingdom, must transfer
produced in Great Britain will
current marketing authorisations
be treated like other medicinal
to a stakeholder established in
products that are imported
an EU/EEA country or appoint a
into the EU/EEA from a 'third
representative in the Community.
country'. After BREXIT,
This also applies to medicinal
pharmaceutical manufacturers
products authorised for the
in the United Kingdom who
treatment of rare diseases (orphan
want to sell medicinal products
drugs).
Documentation of the quality of medicinal products As a starting point, production of medicinal products in the EU/EEA follows the GMP standard, "good manufacturing practice". Medicinal products and active substances produced in the United Kingdom and intended for sale in an EU/ EEA country must therefore in the future be accompanied by a valid GMP certificate that documents that the product lives up to EU quality requirements. For finished medicinal products, an importer must be appointed in the EU/EEA country in which the manufacturer wishes to sell and distribute its medicinal products. The importer must comply with existing rules for the import of medicinal products and semi-finished products into the Community, in order for the importer to be able to release the products for sale. This imposes requirements to the importer’s quality assurance and control, as well as his organisation, staff, facility and equipment, etc.
Qualified Person for Pharmacovigilance The pharmaceutical company’s "Qualified Person for Pharmacovigilance" (QPPV) must be a resident in the EU/EEA. As a consequence of BREXIT, the QPPVs who are connected to MAHs situated in the United Kingdom, will be forced to move to an EU/ EEA country to be able to continue their work tasks. Alternatively, a MAH may appoint a new QPPV who is already a resident within the EU/EEA. The Danish Medicines Agency expects that a QPPV is routinely present in the company, is familiar with all of its premises, and is present for a minimum of 10 hours per week.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
51
GENERIC DRUGS AND BIOSIMILARS
GENERIC DRUGS AND BIOSIMILARS When medicinal products come off patent, generic products stand ready to take major market shares. While original medicines provide innovation, generic drugs and biosimilars first and foremost provide increased access and lower costs. Edited by Arne Jensen -The patent protection of
Hence, as a rule of thumb
there are minor differences
to detect a change in the
innovative original medicines
generic medicines enter
from one batch to another,
quality attributes, Peter
provide exclusivity to the
the market some 10 years
and manufacturers must be
Jørgensen explains.
market. This is obviously
after the original medicinal
able to document that these
of great importance to the
product was granted market
differences do no impact the
society, and is duly reflected
authorization. Generic and
safety and efficacy of the
in revenues. However, on
biosimilar medicinal products
product.
the other side of the ‘patent
provided to the Danish
fence’, generic medicines
market have all been granted
and biosimilars have equally
marketing authorization based
demonstrated value to society
on the regulations outlined
by providing increased
centrally by the European
access as well as lower costs,
Medicines Agency or locally
says Peter Jørgensen, CEO
by the Danish Medical Agency.
at The Danish Generic and
Peter Jørgensen points to
Biosimilar Medicines Industry
the requirements being
Association (IGL).
put in place and described
-As society, innovation is of the utmost importance, and clearly, that’s what the patent protection is there for. But I dare say, once the patent is no longer in effect, sustainable costs of medicines are of equal importance. It is the name of the game.
52
thoroughly by the authorities. The generic small molecules
This may entail evaluating the product at multiple stages, and implies that additional testing and quality control
-For biosimilars a comparability exercise is required, implying that the manufacturer of biosimilars can ascertain that the original and biosimilar drug product is comparable in terms of quality, safety, and efficacy. To reach this goal, the product should be evaluated at the
may be required. -Still, the biosimilars have managed to overcome the initial skepticism upon their entry, and are now duly acknowledged by physicians, national advisory boards, payers, and politicians, Peter Jørgensen ends.
process step most appropriate
must provide data to support that there is no clinically meaningful difference to the original product. But with the introduction of biosimilars the definition of similarity
Facts •
Patent protection is 20 years, and in general for medicinal products this implies exclusivity around 10 years post marketing authorization.
•
The turnover of medicines in Denmark is app. DKK 20 billion / year
•
The proportion of the yearly turnover of medicines in DK pertinent to generic medicinal products amounts to more than 50% at the hospitals and close to 70% at the pharmacies – in volume. This reflects app. 20% in value of the total turnover.
had to be revisited. Even for original biological medicines
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
PATENT TERM EXTENSION
PATENT TERM EXTENSION OF A MAXIMUM OF 5 YEARS Edited by Arne Jensen
A
patent usually expires
for the often lengthy approval
the protection provided by a
lost patent time, an SPC only
after 20 years. In the
procedure. The patent term
patent. Even though an SPC
provides protection for the
pharmaceutical industry the
extension can be extended
is granted to compensate for
approved medicine.
development of new products
by a further 6 months, if the
is often very lengthy, and
marketed medicine has gone
the consequence is therefore
through an approved pediatric
that the patent can only be
investigation plan.
exploited in a fraction of the 20 years.
The SPC is granted to the
Supplementary Protection
European patent on equal
Certificate (SPC), is a patent term extension of a maximum of 5 years, which
patentee of a national or conditions in all of the EU member states.
can be granted to a marketed
The protection conferred by
medicine as a compensation
an SPC is very different to
is the go to international law firm for over 50% of the world’s largest life sciences companies. “There are certain firms that, worldwide, are established as leaders in life sciences, and of course Bird & Bird is one.” - Chambers & Partners
twobirds.com Aarhus & Abu Dhabi & Beijing & Bratislava & Brussels & Budapest & Copenhagen & Dubai & Düsseldorf & Frankfurt & The Hague & Hamburg & Helsinki & Hong Kong & London & Luxembourg & Lyon & Madrid & Milan & Munich & Paris & Prague & Rome & Shanghai & Singapore & Stockholm & Sydney & Warsaw
SPC Requirements: •
The pharmaceutical product must be protected by a patent in force.
•
A valid authorization to place the medicine on the market must be available.
•
The product has not already been the subject of an SPC.
•
The valid marketing authorization must be the first authorization to place the product on the market as a medicine.
DISTRIBUTION
WRONG TRANSPORT CHOICES CAN COST LOSS IN PRECIOUS RESEARCH FUNDING Link PHARMA offers all research institutions and medical companies a safe shipping of research results, samples, etc. There are different shipment methods to choose from and quality guidance and service ensures the optimal solution. Edited by Arne Nielsen
B
irgitte Bosse Knudsen
can talk to them during the
has more than 20 years
process, explains Birgitte
of experience from shipments
Bosse Knudsen who today is
for Global Research in Novo
the Pharmaceutical Transport
Nordisk, and with what
Manager at Link Logistics.
requirements and challenges there are for these types of shipments. Birgitte and Link Logistics had worked together when she was employed by Novo Nordisk and she saw a need for help with the transport of sensitive research material. Birgitte contacted Link PHARMA, which is a department in Link Logistics A/S. - It is important for us that the customer has a good feeling and that they know that their package is being shipped safely. The customer must be confident that the package will be supplied with
When Researchers or Laboratory Technicians have or gets a request of shipping, of important trials that needs to be in fx the United States as soon as possible, it is of highest importance to seek
Jonas Bay Kaas, Pharma Manager
Transport Manager
competent advice, because the wrong transport choices can
Birgitte Bosse Knudsen, Pharmaceutical
become expensive.
Birgitte helps with all the
- We anticipate using our
necessary documents, and
category divisions in C, B,
- The first step in a new
Pharma Manager Jonas Bay
A and A+, where C is the
agreement is to make a
Kaas is a specialist in the
cheapest and A+ the most
thorough agreement of
transportation itself.
expensive. We know that
expectations between the customer and us. What is the correct shipping type? Does the customer want courier, airfreight, car, handheld transport? Can the
- We have answered the expectations from our customers by developing a
startup companies face many challenges regarding their research materials reaching
simple business strategy to
the final customer in good
meet their requirements – we
condition and in due time.
give our clients a small palette
Therefore, Link PHARMA has
fx dry ice or kept at the right
customer withstand losing
temperature if, for example,
of easy and understandable
a special offer for all startup
the shipment? etc. Next, all
held in customs - which
transport solutions based on
companies, he ends.
papers, including customs
the client’s needs, which we
sometimes happens. We know
papers, are prepared, says
call the ABC model, says Jonas
the agents over there and
Birgitte.
and carries on,
A+
Premium
The Safe Choice
B
Standard
C
Economy
Hand-carried shipment
GdP compliance
Express airfreight service
Express courier service
Maximum surveillance and security
GPS tracking and live monitoring temperature measurering
Temperature regulated shipment to consignee’s location
Shipment without temperature regulation
Temperature datalogger
Individual customs
Temperature regulated shipment to consignee’s location
brokerage service
Documented, unbroken cold chain GPS tracking and live monitoring temperature measurering
54
A
Worldwide proactive follow up and track & trace
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
Economically favorable Worldwide proactive follow up and track & trace
PROFILE
DHI assists medtechs to unravel regulatory ambiguities of REACH and MDR With its toxicological expertise and regulatory know-how, DHI is the perfect partner for the medtech industry when embarking on the lengthy process of developing effective and safe medical devices. Not only is choosing the right material crucial, chemical substances used in the device must be evaluated too. Developing effective and safe medical devices is a lengthy process and manufacturers often find it difficult to find their way in the complex legislation. New EU regulation such as the Medical Device Directive (MDR) and the In Vitro Device Directive (IVDR) increases the requirements for documentation of medical devices, while the EU chemicals regulation may impact the substances to be used in the devices as classification and REACHlegislation have consequences on medical devices. “Based on our regulatory know-how, we can help manufacturers of medical devices to evaluate their products. We can also help with chemical registrations and application for authorities as set out in the EU chemicals regulation, REACH, which provides the tools to limit the use of substances with very high concerns, the so-called SVHC’s,” said Brian Svend Nielsen, Senior Toxiclologist, ERT at DHI. However, the interfaces between the different types of legislation and often difficult to detect and sometimes the legislation in one sector may have impact on the legislation in another sector. “A medical device may be manufactured
in EU and contain a problematic substance that is subject to authorisation in REACH, but only if the substance is on the authorisation list due to human health concern, whereas substances subject to authorisation for environmental reasons would require a specific use permission under REACH,” said Nielsen. “A lot of people are not aware of this and that’s a problem.” “We help our customers unravel legal and regulatory issues, for example whether a substance used in the medical device is covered by the REACH obligations or not. There are many overlaps and ambiguities,” said Brian Svend Nielsen. DHI helps manufacturers of medical devices to assess the toxicity of materials and chemical substances, it carries out biocompatibility evaluations and documentation, performs analyses of possible migration of chemical substances when using the medical device, evaluates the need for further tests, and carries out validation of risk assessments. “There’s a lot of focus on the new regulations and standards and you need to be on top of this to get a CE marking of your device,” said Brian Svend Nielsen.
REACH (Registration, Evaluation, Authorisation and Restriction of Chemical Substances) aims to protect human health and the environment through better and earlier identification of the intrinsic properties of chemical substances. Manufacturers and importers of chemicals are required to gather information on the properties of their chemical substances and to register data at the European Chemicals Agency in Helsinki. The Regulation also calls for the progressive substitution of the most dangerous chemicals (SVHC) with suitable alternatives.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
55
LABORATORY & MEDICAL EQUIPMENT
LABORATORY & MEDICAL EQUIPMENT
News From the Industry Edited by Arne Nielsen
Setting a new standard for reversed-phase separations of monoclonal antibodies and antibody drug conjugates In addition to getting performance-driven columns, users of BioResolve brand columns will receive application-focused standards, templated methods, and an enhanced level of applications support to help ensure that they can consistently and reliably perform state-of-the-art bioseparations. “A segment of the scientist community regards mAb and ADC separations as overly complex. The causes of their
Blood culture-free detection of sepsis
frustrations are many and they include poor data quality, degradation of the target mAbs, poor recovery, excessive
T2Candida® is the first sepsis pathogen diagnostic panel
carryover and erratic results due to column-to-column
requiring no blood culture, delivering faster, easier and
irreproducibility. To address these issues, we tasked our
accurate results in an average of 4.3 hours. Run on the T2Dx®
research scientists to engineer a column that would raise
Instrument utilizing T2 Magnetic Resonance (T2MR®)
the bar for separation performance and take the hassle out
technology, the T2Candida Panel rapidly identifies the five
of the measurement process,” said Dr. Erin Chambers, Vice
clinically relevant species of Candida direct from whole
President, Chemistry, Waters Corporation.
blood so appropriate therapy can be initiated. The T2Candida Panel detects the five clinically relevant species of Candida: Candida albicans, Candida tropicalis, Candida parapsilosis, Candida krusei, and Candida glabrata.
”Our ultimate goal is to enable biopharmaceutical scientists to generate consistent results that meet international regulatory requirements to confirm product efficacy and safety.”
In bulletpoints:
• • • •
Species-specific results direct from whole blood with no blood culture in an average of 4.3 hours
With the introduction of BioResolve RP mAb Polyphenyl
Limits of detection as low as 1 CFU/mL
Columns, Waters continues its commitment to the
Accurate results even in the presence of antimicrobials
biopharmaceutical industry by meeting the needs of
Fully automated with limited hands-on time
analytical scientists and lab managers across the discovery, development and manufacturing pipeline.
www.t2biosystems.com For more information: www.waters.com
NYHED Laboratorieglas og -udstyr fra GLASSCO
INTROPRIS SPAR 15%
HAR DU BRUG FOR PRÆCIS DOSERING? DRIFTON TILBYDER ET STORT UDVALG AF PUMPER OG LABORATORIEUDSTYR TIL ATTRAKTIVE PRISER KONTAKT OS, HVIS DU HAR SPØRGSMÅL ELLER BRUG FOR VEJLEDNING TIL DEN RETTE LØSNING
info@drifton.dk Telefon 3679 0000
Tilbuddet er gældende frem til 31.05.2018
Se udvalget på webshoppen www.drifton.dk
LABORATORY & MEDICAL EQUIPMENT
Hospitals can detect fevers earlier thanks to a new wearable device Blue Spark Technologies invented, patented and manufactured TempTraq®, the only wearable, Bluetooth®
Laboratory group Laboratoires Réunis capitalizes genetic information management software suite for complex laboratory reports
continuous temperature monitor, and has received promising
With more than 50 blood sampling locations, a centralized
clinical study results for its medical device. A University
laboratory in Junglinster, Luxembourg, as well as laboratory
Hospitals Seidman Cancer Center (UH) study shows the
sites in Trier, Germany, and Fléron, Belgium, Laboratoires
wearable can detect a rise in body temperature up to 180
Réunis is one of the largest private laboratories in
minutes earlier, in a majority of patient cases, than the
Luxembourg and considered to be a national pioneer for
current standard-of-care (SOC) method, allowing medical
molecular diagnostics and personalized medicine. Apart
professionals the chance to intervene more quickly.
from a broad spectrum of analyses in areas such as clinical
Unlike other devices and methods that provide physicians with only one point of data and offer no continuous monitoring or alerts, this patented device is the ideal, non-invasive, solution for doctors and nurses who need a continuous, smarter way to track, log and respond to fevers quickly.
chemistry or immunology, the Laboratoires Réunis group also offers a number of genetic analyses, a field in which it wants to expand further in future. In order to meet the challenges of efficiently producing high-quality clinical reports during these complex analyses, the lab’s scientists now use bio. logis GIM’s IT solution, specifically designed for this area of application.
To study this continuous, real-time method of body temperature measurement, UH tested the feasibility of monitoring body temperature for patients specifically undergoing stem cell transplant or intensive chemotherapy for leukemia. The patches were applied every 24 hours on 10 neutropenic patients throughout their hospital stays. Body temperature was recorded remotely with TempTraq in 10-minute intervals totaling 14,342 temperature measurements, versus the current SOC of one measurement every four hours.
The starting point is the introduction of the software suite’s “Diagnostic Report Module (DRM)” to largely automate the creation of diagnostic reports on the basis of genetic analysis results. Using a centralized content management system for medical content ensures that the reports are also standardized and always up to date. DRM makes the reporting process highly efficient and improves its scalability. In addition, there are plans to successively introduce more Genetic Information Management Suite modules to further optimize existing processes. Both parties are also working
The TempTraq system is scalable and can support a single
on establishing individual functionalities of the Diagnostic
hospital or a multi-hospital/physician group healthcare
Report Module so that other diagnostic fields also benefit
system.
from enhanced efficiency.
For more information: www.temptraq.com
For more information: www.biologis.com
58
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
10
Press release - February 2018
INNOVATION PRIZE An event by Universal Biotech
8
CALL FOR PROJECTS
INNOVATION PRIZE 2018
Universal Biotech, our consulting company specialized in innovation management for the healthcare sector, has launched the 10th edition of its Universal Biotech Innovation Prize. Each year, the innovation prize awards the most innovative projects in the healthcare field from either young startups (<8 years) or academic research groups. Since 2009, this competition has benefited or benefits from the support and collaboration of many pharmaceutical companies such as GSK, L’Oréal, Pierre Fabre and Servier as well as internationally renowned academic institutions such as ANR, European Commission, Pasteur Institute and the Karolinska Institute. In 2017, for its 9th edition, more than 260 candidates from 31 different countries participated in the competition. Three teams were rewarded: NLS Pharma (Swiss) – Biotech Prize BaseCamp Vascular (France) – Medtech Prize Sinnovial (France) – Digitech Prize WHY SHOULD I PARTICIPATE IN THE 2018 INNOVATION PRIZE? By submitting your project to Innovation Prize 2018, you will increase its exposure within the Life Science market and help introduce it to potential partners and investors. Your project will also be assessed by leading experts who will provide you with expert advice and feedback to help you optimize your business plan. Each laureate will also win up to €30 000 in the form of a cash prize and consulting services from Universal Biotech. HOW CAN I PARTICIPATE? Three prizes will be awarded for this 10th edition: the Biotech Prize, the Medtech Prize and the Digitech Prize (health NICTs including e/m-health, platforms and connected objects). The project leader can apply online by filling out an application on our call for projects platform, Open Innovation Access. The platform will remain open until April 30th, 2018. Our jury panel, made up of international experts from pharmaceutical companies and academic institutions, will assess your project based on the following criteria: Scientific quality of the innovation Team expertise and diversity Intellectual Property strategy Project feasibility Chances of success on the market The Innovation Prize 2018 awards ceremony will take place next October in Paris. Innovation Prize Team prix-innovation@universal-biotech.com
CONTACT: Olivia MIOSSEC - +33(0)1 41 12 27 87- olivia.miossec@universalmedica.com FOR MORE INFORMATION, VISIT THE WEBSITE: www.universal-biotech-prize.com
LABORATORY & MEDICAL EQUIPMENT
Innovative biomedical technologies from the Graphene Flagship Graphene and related materials are paving the way for novel
The Graphene Flagship showcased four demonstrators of
biomedical diagnoses and treatments thanks to their unique
innovative biomedical technologies at the MEDICA 2017
properties such as high surface area, electron mobility and
exhibition in Germany. Funded by the European Union
surface functionalization. For instance, the surface area of
Graphene Flagship partner Catalan Institute of Nanoscience
graphene makes an excellent platform for drug delivery and
and Nanotechnology displayed two of these demonstrators:
the conductivity allows for effective biosensors. The ability
a graphene sensor able to detect the electrical activity of the
of graphene to be made into scaffolds whilst maintaining the
brain providing early detection for neurological events such
inherent conductivity can be used in tissue engineering. New
as epileptic seizures; and a retinal implant which can serve as
research has shown that graphene can also be incorporated
optical prostheses for people who have lost their sight. A fully
with a polymer to make electromechanical sensors and
functional robotic hand controlled by graphene sensors was
deep brain implants. Professor Andrea C. Ferrari, Science
demoed by Flagship Partner Istituto Italiano di Tecnologia
and Technology Officer of the Graphene Flagship and
(IIT); IIT is developing this research project with INAIL, the
Chair of its Management Panel said â&#x20AC;&#x153;Health, Environment
Italian National Institute for Insurance against Accidents at
and Bio-Medical applications are part of the roadmap for
Work. The Graphene Flagship Partner Guger Technologies
graphene and related materials. We are excited to present
(g.tec), headquartered in Austria, presented a brain computer
innovative devices to medical professionals and companies.
interface containing graphene electrodes capable of
This is yet another step towards the full development of
measuring brain activity.
novel biomedical solutions enabled by graphene and related materials.â&#x20AC;? For more information: www.graphene-flagship.eu
60
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
LABORATORY & MEDICAL EQUIPMENT
FocalSpec’s UULA answers the demand for automated quality control in fast-growing medical device markets FocalSpec, the Finnish expert in highprecision quality control devices, launched their first 3D imaging and metrology system UULA. UULA can be used both in at-line quality control and in laboratories. It works especially well in measuring 3D topography and dimensions in medical device manufacturing as well as studying seal integrity of medical packages. UULA can be used to inspect a variety of medical devices and components where the parts must be designed on a micron scale to ensure the devices’ operational reliability. Chips used in microfluidic analysis can also be inspected, as well as biosensors. The former can be used in detecting
Hjælp et talent godt på vej, ta’en studerende i praktik
the outbreak of cancer and the latter in measuring blood sugar or drug concentration in the human body. The research made in the field of medical devices, as well as product development and quality control processes, can be made more efficient and safe through automatization. As an example, the seal quality of sterile packages in operating rooms has traditionally been inspected manually. This has also had the effect of destroying the inspected package. With UULA, the inspection is quick and accurate, and the product doesn’t suffer in the process, a result that saves resources as well as reduces waste.
For more information: www.focalspec.com
61
Dansk Laborant-Forening/HK Weidekampsgade 8 Postboks 470 0900 København C Tlf. 33 30 44 70 E-mail: dlf@hk.dk www.dl-f.dk
8
COMPANY INDEX
64 | Academic Institutions and Support Structure Organisations 66 | Business Service Providers 68 | Contract Research Organisations 69 | Laboratory, Medical & Pharmaceutical Equipment 71 | Contract Manufacturing Organisations 71 | Other
COMPANY INDEX
Academic Institutions and Support Structure Organisations The Department provides the research framework for the engineering study programmes in Medical Biotechnology, Biotechnology, Chemical Engineering and Environmental Engineering as well as the Chemical and Biological Sciences Programs. In both teaching and research the department combines theory and practice and emphasize collaboration with companies and public sector organizations both nationally and internationally. The department offers both Bachelor (Bsc) and Master (Msc) programs as well as regular PhD courses.
Department of Chemistry and Bioscience Aalborg University Fredrik Bajers Vej 7H DK-9220 Aalborg T: +45 9940 3605 E: info@bio.aau.dk W: www.en.bio.aau.dk
Lif Uddannelse, Medicademy and DLI Udstilling, are now Atrium – a living, dynamic space where Life Science professionals come to learn, connect and network. Atrium is a place rich in tradition, insights and inspiration – an environment where opinions and knowledge are shared. We’re passionate about offering valuable learning experiences that help you advance professionally. Atrium Lersø Parkallé 101 DK-2100 Copenhagen T: +45 39 27 60 60 W: www.atriumcph.com
With more than 25 years experience in meeting the diverse needs of the biotech and pharma industry, Bioneer is ready and able to deliver competitive and on-time solutions to companies, large as well as small. Explore our expertise in your area of interest on our website for an example within drug development, biomarkers, protein manufacturing, immune targeting, active ingredients and microorganisms, licensing opportunities etc. Bioneer A/S Kogle Allé 2 DK-2970 Hørsholm Tel. +45 4516 0444 E-mail: bioneer@bioneer.dk Web: www.bioneer.dk
Business Ballerup Municipality of Ballerup Hold-an Vej 7 DK-2750 Ballerup T: +45 4477 2000 E: businessballerup@balk.dk W: www.ballerup.dk
Copenhagen Capacity Nørregade 7B DK-1165 Copenhagen T: +45 3322 0222 E: info@copcap.com W: www.copcap.com
64
The Municipality of Ballerup, a suburb to Copenhagen has a population of 48,231. Ballerup is part of a regional workforce. Every day, almost 35,000 commutes to Ballerup to work. Jobs: 45,000 – 34,500 private sector jobs and 10,500 public sector jobs. Ballerup is the municipality in Denmark with the most foreign corporations with a 25,5% share. The municipality has the highest rate of IT employees in Denmark with 22% of the total amount of jobs. Also it has the highest hourly rate at DKK 294 (Source: The Municipality of Ballerup). The Life Science cluster in Ballerup employs 4,900 people in more than 30 corporations, making it the second biggest life science cluster in the country after Gladsaxe (Source: Medicon Valley Alliance).
Copenhagen Capacity is the official organisation for investment promotion and economic development in Greater Copenhagen. The organisation supports foreign companies, investors and talent in identifying and capitalising on business opportunities in Greater Copenhagen - from initial considerations to final establishment. Copenhagen Capacity is the leading expert on developing and implementing business opportunities in Greater Copenhagen. Copenhagen Capacity’s services are free of charge for all foreign-owned companies, who want to establish or invest in Greater Copenhagen, and provided in full confidentiality.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
COMPANY INDEX
Dansk Laborant-Forening er en tværgående landsforening under HK, som er et af Danmarks største fagforbund med omkring 300.000 medlemmer. Det betyder, at alle, der er medlem af Dansk Laborant-Forening, samtidig er fuldgyldigt medlem af HK og dermed nyder godt af alle medlemsrettighederne her. Som organiserede i HK kan vi derfor bruge HK's konsulenter i f.eks. arbejdsmiljø-, uddannelses- og juridiske spørgsmål. DL-F / HK Weidekampsgade 8 Postboks 470 0900 Copenhagen C Tel. +45 3330 4470 E-mail: dlf@hk.dk Web: www.hk.dk
DTI (The Danish Technological Institute) Gregersensvej 1 2630 Taastrup Tel. +45 7220 2000 E-mail: info@teknologisk.dk Web: www.dti.dk
We collaborate with universities, hospitals and private companies within medical, pharmaceutical and biotech industries. In particular, we have experience in R&D projects within the areas of infection diagnostics and biomarker development. We perform accredited standard analyses and customized development tailored to meet the needs of our clients and projects. We have extensive experience in both national and international R&D projects, e.g., Innobooster, Eurostars and EU projects. We offer an array of analyses and technologies for biomarker discovery, DNA- and RNA-based molecular biology, proteomics, protein characterization, biofilm characterization, antimicrobial solutions and in vitro systems.
The Faculty of Health and Medical Sciences is an important part of a dynamic interaction with the surrounding community. The purpose of this interaction is to use our knowledge to create value for citizens and improve general health. For this reason, our core task is to educate talented students who can go on after their graduation to devote their strong skills to their working lives. The faculty constantly discovers valuable new insights that can contribute to growth and employment in the community.
Faculty of Health and Medical Sciences University of Copenhagen Blegdamsvej 3b 2200 Copenhagen N Tel. +45 3532 7900 E-mail: email@sund.ku.dk Web: www.healthsciences.ku.dk Lundbeckfonden awards anually the 1 mio. € Brain Prize. Lundbeckfonden is an active industrial foundation established in 1954. Its main objective is to maintain and expand the activities of the Lundbeck Group, and to provide funding for scientific research of the highest quality. The Foundation annually grants DKK 400 - 500 million to support medical research of the highest quality and supports educational and communication activities related to science. Lundbeckfonden, The Brain Prize Scherfigsvej 7 DK-2100 Copenhagen Ø Tel. +45 3912 8000 E-mail: info@thebrainprize.org Web: www.thebrainprize.org Medicon Valley Alliance (MVA) is a non-profit membership organization in the Danish-Swedish life science cluster Medicon Valley. Our approx. 230 members, who together employ approximately 140.000 people, represents the region’s triple helix and include universities, hospitals, human life science business, regional governments and service providers. We create value for our members by co-hosting, launching and driving meetings, working groups, seminars, conferences and projects, that strengthen the collaboration, networking and knowledge-sharing in the regions life science community, create critical mass and help realizing the full potential of Medicon Valley.
Medicon Valley Alliance Arne Jacobsens Allé 15, 2. Ørestad City DK-2300 Copenhagen S Phone: +45 70 20 15 03 Email: mva@mva.org www.mva.org
Workindenmark East Gyldenløvesgade 11 1600 København Tel: +45 7222 3300 E-mail: workindenmark@workindenmark.dk Web: www.workindenmark.dk
Workindenmark provides international jobseekers and Danish employers with the information, guidance and tools to find each other. Workindenmark is a public employment service for highly qualified international candidates looking for a job in Denmark, and Danish companies searching for talented foreign candidates. Workindenmark is part of the Danish Ministry of Employment and member of European Employment Service (EURES). There are three Workindenmark centres, located in Copenhagen, Odense and Aarhus.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
65
COMPANY INDEX
Business Service Providers When choosing your regulatory partner is a matter of trust. A-consult group offers the whole palette of Regulatory Affairs, Quality and Vigilance. We know that very project and every client is different. Our objective is to ensure that you get the best professionals every time.
A-consult a/s Gladsaxevej 382 DK-2860 Søborg T: +45 38330080 E: a-consult@a-consult.dk W: www.a-consult.com
A-consult group offers solutions adapted to your timelines and your budget in compliance with local regulations.
We provide highly qualified engineering consultancy within all disciplines relating to project management, GMP compliance, technical advice, production efficiency and process verification in the pharmaceutical-, biotechnological-, medical device- and food industry. Andreasen & Elmgaard A/S possesses expert skills acquired through many years of extensive industry experience and can contribute with valuable consultancy throughout an entire project - from the initial design phase to the final launch of the product, and continuous process optimization. Key-areas include, but are not limited to the following, project management, technical know-how, process verification, quality assurance (GMP), equipment qualification and process validation.
Andreasen & Elmgaard A/S Generatorvej 8C, 2. Th. DK-2860 Søborg T: +45 3117 8232 E: sales@aoge.as W: www.aoge.as
Best Talent is specialized in Executive Search and Selection within Engineering, Pharma and Life Science. Best Talent has quickly grown to become the favorite collaborative partner as a result of our experience, background and network. We solve projects on both a tactical and strategic level. We “speak the language”, know the market and attract highly qualified candidates. We possess the largest and most desired talent database in the field with over 10,000 life science candidates.
Best Talent A/S Rungstedvej 41 DK-2970 Hørsholm Tel. +45 4556 5300 E-mail: info@besttalent.dk Web: www.besttalent.dk
Bird & Bird is an international law firm, with a rare and invaluable grasp of strategic commercial issues. With over 240 experts globally and a wealth of hands-on experience from working in life sciences and healthcare companies and regulatory bodies, clients choose us as their strategic partner to guide them through some of their most complex legal challenges. Bird & Bird Sundkrogsgade 21 DK-2100 København Ø Tel: 72 24 12 12 E-mail: Denmark@twobirds.com Web: www.twobirds.com
Bird & Bird is the go to international law firm for over 50% of the world’s largest life sciences companies.
THE MOST ADVANCED CLEANROOM LAUNDRY IN SCANDINAVIA • Traceability, validated processes and documentation based on innovative cleanroom technology. • Specializes in on-site training of operators in correct use of cleanroom clothes and cleaning articles. De Forenede Dampvaskerier - DFD Cleanroom V. Henriksens Vej 6 DK-4930 Maribo Tel.+45 4422 5560 / +46 406 566 500 E-mail: crmar@dfd.dk Web: www.dfd.dk
• Preferred partner of unique cleanroom solutions in accordance to ISO and GMP compliance. For more information: www.dfd.dk
Advanced manufacturing facilities and processes are necessary to satisfy the exacting requirements of both consumers and the authorities. When you need inspections, testing and certification, we can help you to meet the requirements of national and international standards relating to quality, the environment, workplace environment management systems and audits. We can also offer you consultancy and services that enable you to improve your production processes and facilities. FORCE Technology Park Allé 345 DK-2605 Brøndbyvester T: +45 43 25 00 00 E: info@forcetechnology.dk W: www.forcetechnology.com
66
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
COMPANY INDEX
At DHI, we possess an extensive knowledge base related to chemicals regulations worldwide, with respect to product safety. Moreover, we have an established network of contacts with national authorities on worldwide markets. We’re therefore well placed to support you efficiently in bringing your products to the market. We can effectively help you to fulfil regulation and instruction requirements as well as standards and local labelling. For pharmaceutical products, we can help you develop strategies as well as monitor and interpret experimental studies. DHI Hørsholm - Head Office Agern Allé 5 2970 Hørsholm Tel. +45 4516 9200 E-mail: dhi@dhigroup.com Web: http://www.dhigroup.com/ Elite Miljø performs classified cleanroom cleaning in the pharmaceutical industry and hospital sector. We work with both high and low classified cleanrooms. We offer a complete cleaning solution where we have management and control over the entire process.
Elite Miljø Ormhøjgårdvej 12 DK-8700 Horsens Tel. +45 7015 4800 E-mail: info@elitemiljoe.dk Web: www.elitemiljoe.dk Cross cultural management, cooperation and communication. We help staff at major life science organisations succeed in an international multicultural working environment. Our activities include:
GlobalDenmark a/s Hauchsvej 14 DK-1825 Frederiksberg C T: +45 3386 2930 E: global@global-denmark.dk W: www.global-denmark.dk
• • • • • • •
Management and cooperation in the multicultural team Negotiation techniques Presentation techniques Cross-cultural knowledge-sharing Cross-cultural feedback techniques Scientific and business English Translation and proofreading
Jusmedico Advokatanpartsselskab Klampenborgvej 248, 1. m.f. DK-2800 Kgs. Lyngby T: +45 4548 4448 E: jbb@jusmedico.com / mbl@jusmedico.com W: www.jusmedico.com
Jusmedico is a specialist law firm providing legal services to the biotech, pharmaceutical, medical device, food supplement & dentistry industries, life science investors and to suppliers and service providers thereto. Internationally Jusmedico is co-founder and member of BioLawEurope F.m.b.A. a network of independent law firms from EEA countries and Switzerland, specialized in the rendering of legal services to clients facing life science related legal challenges. Moreover Jusmedico operates a representative office in New York, USA. In 2016, 2017 and 2018 Jusmedico has been awarded the Corporate INTL Global Award Price as Biotech Law Firm of the Year in Denmark. At Link Logistics, we’re passionate about our customers and our values – and both are cornerstones in everything we do. Your transportation is organized across the world’s leading logistics companies. We are your global and independent logistics link that makes sure your shipments reach their destination quickly and securely on time – always aided by innovative technology. Our entire staff is passionate about helping you through professional, close and personal service offered by specialists within all areas of logistics. At Link Logistics, we believe that it’s the small things that make the big difference.
Link Logistics A/S Vallensbækvej 51-53 DK-2605 Brøndby T: +45 3248 8873 E: linkpharma@linklog.dk W: www.linklog.dk
World Courier Denmark A/S Avedoereholmen 96-98 DK - 2650 Hvidovre (Copenhagen) Tel. +45 32 46 06 80 E-mail: ops@worldcourier.dk Web: www.worldcourier.com
At World Courier, each trusted partnership we form with a customer is deeply rooted in our shared vision of improving global health, and it starts with gaining a holistic understanding of your strategic business objectives. With this knowledge in hand, we design and execute world-class logistics processes that mitigate risk, maximize the return on R&D investments and advance medicine. No other specialty logistics company has the experienced personnel, global offices and in-market expertise required to ensure the optimal handling, transport and delivery of vital healthcare products.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
67
COMPANY INDEX
Contract Research Organisations A+ Science is a complete clinical service Contract Research Organisation (CRO) with two decades of experience in clinical services within pharmaceutical (Phase I-IV) and medical device studies and across a broad range of therapeutic indications. Our core expertise is in the Nordic Countries, however through our close collaboration with other CROs, we cover several other countries. We offer flexible solutions and customised services to our customers. Since December 2013, A+ Science is a CRO run by its employees. A+ Science Luntmakargatan 22 111 37 Stockholm SWEDEN T: +46 (0)73 67 441 22 E: info@a-plusscience.com W: www.a-plusscience.com
CroxxMed ApS Agern Allé 24 DK-2970 Hørsholm Mobile: +45 2015 1221 E-mail: bte@croxxmed.com Web: www.croxxmed.com
Our vision is to become the CRO best known for its unique and dedicated personnel with focus on customer satisfaction. To Earn Trust- Make Difference.
At CroxxMed we are a team of experienced personnel striving to make your experience as smooth as possible. Nordic by nature, we provide complex knowledge built on a solid foundation of years in clinical research within many different therapeutic areas. CroxxMed offers services in all phases (I-IV); clinical operation, regulatory affairs, data management, statistics, medical writing, pharmacovigilance, and consulting services for all types of medical device studies. We are at all times updated on the market. At any time, fully in tune with the regulatory requirements and trends in the industry. We are less boring than average and you are our top priority.
DB Lab is a GMP contract laboratory with more than 20 years of experience. We offer chemical, physical and microbiological analyses on raw materials, intermediates, finished products, and process samples to the pharmaceutical and biotechnological industries. We value ongoing dialogue with our partners in order to provide the best service possible. Quality and credibility are core values to both our partners and to DB Lab.
DB Lab A/S Lille Tornbjerg Vej 24 DK-5220 Odense SØ Tel. +45 6593 2920 dblab@dblab.dk www.dblab.dk Larix is a full service Clinical Research Organization, offering assistance in all aspects of clinical trials (phase I-IV): Clinical operations, statistics, data management, medical writing, system validation, GCP, vendor audits and pharmacovigilance. We work with all types of pharma/biotech/medtech/diagnostic companies. We are here for the patients, our employees and our customers. We take pride in being passionate and dedicated, delivering high quality on time. Key focus is oncology. We have offices in all Nordic countries. Larix A/S Lyskær 8b DK-2730 Herlev Tel. +45 7027 2221 E-mail: info@larixcro.com Web: www.larix.dk LINK Medical Research is a Scandinavian full-service Contract Research Organisation (CRO), offering project management and product development services for the pharmaceutical and medical device industry. At the beginning of 2018, its new LINK Medical RWE department opened.
LINK Medical Research Vester Voldgade 96, 2.tv. DK-1552 København V T: +45 22 15 85 56 E: link@linkmedical.dk W: www.linkmedical.no
68
LINK Medical Research has recently established the LINK Medical RWE department, which will see a further strengthening of the CRO’s focus on Real World Evidence. LINK Medical now offers a full palette of services for the pharmaceutical and medical device industry, but it stays true to its core values, which has been at the heart of the company since the beginning. LINK Medical Research has offices in Oslo, Malmø, Copenhagen, Stockholm and Berlin.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
COMPANY INDEX
Laboratory, Medical & Pharmaceutical Equipment • • • • •
IT/MES/MIS – Recipe-, Batch, Serialization, Traceability, OEE, Audit trail AUTOMATION – PLC, SCADA, DCS, VISION for Process-, Machine- and Quality control VALIDATION – Process-, Computer-, Machine-validation, GMP Compliance OPTIMZATION – Lean, Production improvements PROJECT MANEGEMENT
CONSULTANCY – SERVICES - PROJECT DELIVERIES – AN Group A/S Mejeribakken 8 DK-3540 Lynge T: +45 48 25 10 00 E: info@angroup.dk W: www.angroup.dk
ApodanNordic PharmaPackaging A/S Kigkurren 8M 2300 København S Denmark Phone +45 32 97 15 55 E-mail: packaging@apodanpharma.dk
Buch & Holm A/S Marielundvej 39 DK-2730 Herlev T: +45 4454 0000 E: b-h@buch-holm.dk W: www.buch-holm.dk
Apodan is the leading supplier of pharmaceutical packaging items in the Nordic. Our main activities are development, production and sale of a wide range of pharmaceutical packaging items. Our products are sold worldwide, and the Nordic countries are the primary market area. We are specialists in standard packaging solutions as well as in customized packaging solutions, which is developed in close cooperation with the customer. Visit us at www.apodanpharma.dk
Over the years Buch & Holm has developed into a company that adapts quickly to dynamic market conditions. This is achieved through know-how, consulting and competent personnel. In recent years, Buch & Holm has experienced strong growth, and today the company is one of the market leaders as a total supplier of equipment, inventory and consumables to laboratories, quality control and the industry. It’s all about adding value to the things we do. WE KNOW WHAT IT TAKES.
Daintel is specialised in Patient Data Management Software for Intensive Care and Operation Wards. The company enjoys a leader's position in Denmark and in Iceland. The solution has been developed by clinicians for clinicians and is the only solution in the world to save all patient data as time-stamped in high-resolution for research purposes. SHARING EXPERTISE
Daintel Diplomvej 376, DTU DK-2800 Lyngby Tel. +45 7027 4470 E-mail: info@daintel.com Web: www.daintel.com Diatom is an engineering & trading company, which since 1964 has represented international contacts in Denmark with market leading products where we have a commitment to achieving customer satisfaction by providing innovative, total system solutions that add value to our customer by improving manufacturing efficiency, reliability and quality. Diatom A/S Avedøreholmen 84 DK-2650 Hvidovre Tel. +45 3677 3600 E-mail: info@diatom.dk Web: www.diatom.eu
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
69
COMPANY INDEX
Drifton A/S offers a wide range of laboratory pumps and dispensing devices for use in laboratories. Our range of laboratory pumps includes peristaltic pumps, micro gear pumps and syringe pumps. We offer a wide range of ancillary products for the peristaltic pumps e.g. peristaltic pump tubing, dispensing nozzles, weights for tubing, luer lock adapters and tube connectors. Drifton A/S Avedøreholmen 84 DK-2650 Hvidovre T: +45 3679 0000 E: info@drifton.dk W: www.drifton.eu
Our laboratory products include laboratory glassware, pipettes, bottle-top dispensers, hotplates and magnetic stirrers.
Gammadata Instrument AB- Your partner in bioimaging Gammadata, founded in 1987, is a leading supplier in the Nordic and Baltic countries for all your bioimaging needs.
Gammadata Instrument AB P.O. Box 2034 SE-750 02 UPPSALA T: +46 (0)18-56 68 00 E: info@gammadata.se W: www.gammadata.se
We represent Horiba fluorescence and Raman microscopes, Femtonics 2-photon microscopes coupled to Coherent femtosecond lasers, in addition to lasers for confocal microscopy, Phenom World desktop SEM and CLEM systems, as well as AFM systems from Keysight. With the latest imaging techniques demanding the highest resolution we also provide anti-vibration tables from TMC Ametek to ensure the best quality images for your scientific publications.
Ultra rent vand er grundlæggende i alle effektive laboratorier, der arbejder med følsomt apparatur og kemiske og molekylærbiologiske analyser. Krüger Aquacare forhandler en række af ELGAs vandanlæg. Vi tilbyder et bredt spekter af helhedsorienterede løsninger til laboratorier, der stiller høje krav til deres leverandører. Krüger Aquacare Fabriksparken 50 DK-2600 Glostrup T: +45 4345 1676 E: aquacare@kruger.dk W: www.kruger.dk
Læs mere om vores professionelle løsninger her: http://www.kruger.dk/industri/loesninger/laboratorievand/
LabWare has delivered powerful lab automation solutions to many different industries. LabWare's single core product strategy benefits every LabWare customer because it enables all of our development, support and implementation resources to focus on a common solution. The LabWare technical architecture facilitates easy upgrades and functionality enhancements, so our customers are always current and remain well supported. LabWare Nordic Landskronavägen 25A SE-Helsingborg 252 32 T: +46 4237 5860 E: infoNordic@labware.com W: www.labware.com
Particle Measuring Systems Korskildelund 4-6 DK-2670 Greve T: +45 7070 2855 E: pmsnordic@pmeasuring.com W: www.pmeasuring.com
LabWare has created pre-configured Template Solutions to suit the requirements of specific industries. LabWare's Template Solutions leverage our experience with implementing LabWare LIMS and LabWare ELN into many different industries. Template Solutions are now available for the following domains: Pharmaceuticals, Environmental Testing, Contract Labs, Forensics, Chemical/Petrochemical Process, Public Health, Clinical Research, Bioanalysis DMPK, Food, and Biobank.
Since 1972, Particle Measuring Systems has been the global expert in contamination monitoring, providing the pharmaceutical and other life science industries with the expertise to detect, analyze and manage cleanroom contamination so you can meet all regulatory requirements including ISO 14644-1:2015 and EU GMP Annex 1. As one of the world’s leading clean room contamination control experts<https://www.pmeasuring.com/en/about-us> and complete solutions provider, we offer fully integrated and robust monitoring solutions including: • Particle Counters and Microbial Samplers, remote and portable • Environmental and Facility Monitoring Systems • Data collection and Data Management (DM) • Advisory services including risk management and crisis handling • GMP Services
Siemens Healthineers offers a wide selection of diagnostic solutions for effective testing in in-vivo and in-vitro diagnostic. We continuously expand our value-added services – based on our broad portfolio of highly innovative medical technology. By introducing new enterprise and digital services, along with new business models, we strive to maximize opportunities and minimize risks for healthcare providers – transforming healthcare systems all together Siemens Healthcare A/S Borupvang 9 DK-2750 Ballerup Tel. +45 4477 4477 Web: www.healthcare.siemens.dk
70
See www.healthcare.siemens.dk for more information.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
COMPANY INDEX
SSI Diagnostica A/S Herredsvejen 2 3400 Hillerød T: +45 4829 9100 E: info@ssidiagnostica.com W: www.ssidiagnostica.com
SSI Diagnostica A/S develops, produces and sells the best in vitro products available in the market. A flexible and customer-oriented approach provides you with thoroughly tested and innovative quality products at the right time. With more than 100 years of experience we ensure you the right answers on your tests. A proud tradition for research in Denmark is the foundation for our products making a difference in more than 50 countries. Experience Matters.
Svanholm.com is a supplier of High-End Analyzers, Sensors and Equipment for biotech, biofuel, crystallization, stem cells, tissue engineering and tablet manufacturing areas. We distribute products of 25 suppliers in the Nordic countries, and we cover from raw material identification with Raman over solvent drying control with mass spectrometers to fermentation pH, DO, OD and Viable Cell Density sensors. Svanholm.com Nordic Pharma and Analyzer Center Marienbergvej 132, 1. DK- 4760 Vordingborg Tel. +45 7026 5811 E-mail: mail@svanholm.com Web: www.svanholm.com
Contract Manufacturing Organisations Cambrex is an innovative life science company with a refreshingly human approach. Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers’ small molecule therapeutics into markets across the world. With over 35 years of active pharmaceutical ingredient (API) development and manufacturing expertise, a growing team of more than 1,200 experts and a strong presence in the USA and Europe, we are tried and trusted across branded and generic API markets. Cambrex has facilities in the US (Corporate), Sweden, Germany, Italy, Estonia. Cambrex is also active in the Danish market. Cambrex Björkborns Industriområde 691 33 Karlskoga Sverige Tel. +46 586 78 30 00 Web: www.cambrex.com
Other Door System deliver durable door solutions that live up to the strict requirements to materials, hygiene and reliability in the pharmaceutical industry. Easy access to 100 % cleaning. Automatic controls encapsulated in stainless and waterproof boxes. No visible screws or fitting plugs. Interlock system between doors. Safety sensors on all automatic doors. For further details, please contact Søren Rahbek, phone +45 42 14 52 02, sr@doorsystem.dk Door System A/S Hovvejen 148 DK-8361 Hasselager Tel. +45 86 92 11 71 www.doorsystem.dk
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
71
THE MEDICON
YEAR 72
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
VALLE Y
BOOK
2 018
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | Y E A R B O O K 2018
73
CALENDAR
HIGHLIGHTED FAIRS AND EVENTS IN 2018 RISK MANAGEMENT AND RISK BASED MONITORING IN A CLINICAL RESEARCH SETTING Date: 23.05.2018, Copenhagen, Denmark
www.atriumcph.com/course/Risk-Management-and-Risk-Based-Monitoring-in-a-Clinical-Research-Setting/21702 This course will allow you to appraise your current processes, people and technology with a view to improve monitoring and site efficiency and enhancing patient protection while maintaining high quality data.
Take the opportunity to practice the necessary skills to apply a risk based approach to monitoring activities. We will review the principles of risk management and how to apply them within a clinical research or monitoring setting. The impact of introducing a risk based approach on site processes is also considered.
CONFERENCE ON BIG DATA IN BIOTECHNOLOGY AND BIOMEDICINE Date: 31.05.2018 â&#x20AC;&#x201C; 01.06.2018, Hotel Munkebjerg, Vejle, Denmark
www.biokemi.org or www.ida.dk The conference will focus on the latest developments in creating, utilizing, handling and methods for analyzing Big Data in biotechnology and biomedicine including sessions on, precision medicine, statistical genetics, single cell analysis, systems biology in medicine and process biotechnology, biological and genomic networks, microbiomics and best practice on
handling and storage, safety and ethics. The conference is organised in collaboration with Danish Society of Biochemistry and Molecular Biology and includes a poster session as well as a commercial exhibition of equipment, consumables and services to Danish biotechnology.
NORDIC LIFE SCIENCE DAYS 2018 Date: 10.09.2018 â&#x20AC;&#x201C; 12.09.2018, Stockholm, Sweden
www.nlsdays.com Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science, and created a unique place to do business. Most attendees express their delight in the informal atmosphere, combined with an organized approach to meeting highly relevant people. The conference has
74
created a space for meaningful encounters, with oneon-one meetings being one of the main features of NLS Days. Additionally, the high quality of topics and presenters provide insight into the most recent trends in science and business. NLS Days attracts leading decision makers from biotech, pharma and medtech as well as finance, research, policy and regulatory authorities.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | M A RC H 2018
CALENDAR
LABDAYS COPENHAGEN 2018 Date: 12.09.2018 – 13.09.2018, Copenhagen, Denmark
www.labdays.dk This year the CPH LabMed exhibition has changed to a new LabDays Copenhagen concept. The changes result in the fair moving to a new venue central in Copenhagen. The fair will be conducted over 2 days instead of the usual 3 days. A new turnkey stand concept is introduced and the fair gets a new stand layout,
meanwhile the possibility of custom made stands is maintained. The Danish Society for Mass Spectrometry will organize a theme day in parallel with LabDays Copenhagen, and also, the Laboratory Medical Society for Bioanalysts (LSB) will conduct their theme day and their annual meeting in parallel with the exhibition.
THE UNIVERSAL BIOTECH INNOVATION PRIZE 2018 Date: The award ceremony will take place in Paris in October 2018 – not yet determined date.
www.universal-biotech.com The consulting company Universal Biotech has launched the 10th edition of its Innovation Prize. The Universal Biotech Innovation Prize rewards the most innovative projects in the healthcare sector. Universal Biotech is looking for both young startups (less than 8 years old) and academic researchers currently developing an innovative project, from discovery to pre-market stage.
This year, the Innovation Prize 2018 will reward projects in the fields of biotech, medtech and digitech. Each laureate will win up to 30,000.00 euros in the form of cash and consulting services. The deadline for applications is April 30th 2018. Applications can be submitted through the prize’s online Open Innovation Access platform: https://www.universal-biotech-prize.com/
BIO-EUROPE 2018 Date: 05.11.2018 – 07.11.2018, Copenhagen, Denmark
www.ebdgroup.com For the first time ever, Bio-Europe will be conducted in Medicon Valley. The event offers powerful opportunities for you to network with the right partners, and brings together hundreds of the world’s most innovative leaders across biotech, finance and pharma for high-level networking, pre-scheduled partnering
meetings, strategic panel discussions and more. Last year the event attracted more than 4,000 attendees, 2,199 companies from more than 60 countries. 24,199 one-to-one meetings were held, 5,142 licensing opportunities were posted, 152 company presentations held and 106 exhibitors were present.
DIPLOMA IN CLINICAL PROJECT MANAGEMENT Date: 26.11.2018 – 28.11.2018, Copenhagen, Denmark
www.atriumcph.com This is for you who works with clinical development and wishes to develop your competencies and skills
within project management.
G R E AT ER CO P EN H AG EN L I F E S CI EN C E | M A RC H 2018
75
Clester Oxendine Senior Research Associate QC
Active ingredients | Dynamic people Our people are at the heart of everything we do and every Cambrex success. That’s why customers say we’re the experts they enjoy working with. Discover why we’re one of the biggest names in small molecule APIs at
www.cambrex.com
Custom development & manufacturing
Generic APIs
Controlled substances